Access DB# 76828

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Alysia Berman Examiner #: 76457 Date: 9/30/02
Art Unit: 1617 Phone Number 308-4638 Serial Number: 09/892,252
Mail Box and Bldg/Room Location: 3D12 Results Format Preferred (circle): PAPER DISK E-MAIL
2019

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See attached

Inventors (please provide full names): See attached

Earliest Priority Filing Date: 6/27/01

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Jan,

Please search all compounds and sequences by name and structure with hair growth or reduction. Elected species are claims 2 & 18.

Thanks,
Alysia

Approved
T Kopec
SPE, AU 1615

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Jan	NA Sequence (#) ✓	STN ✓
Searcher Phone #: 4498	AA Sequence (#)	Dialog
Searcher Location:	Structure (#)	Questel/Orbit
Date Searcher Picked Up: 10/1/02	Bibliographic ✓	Dr.Link
Date Completed: 10/1/02	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems ✓
Clerical Prep Time: 30	Patent Family	WWW/Internet
Online Time: + 400	Other	Other (specify)

PTO-1590 (1-2000)

```
=> d his

     (FILE 'HOME' ENTERED AT 14:16:18 ON 01 OCT 2002)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 14:16:37 ON 01 OCT 2002
               E TTAGGGTTAGGGTTAGGG/SQEN
L1          57 S E3
               E ACGTTGAGGGGCATC/SQEN
               E ATGAAAATCAGGGTTAGG/SQEN
               E CAGUUAGGGUUAG/SQEN

     FILE 'REGISTRY' ENTERED AT 14:19:03 ON 01 OCT 2002
L2           8 S CAGUUAGGGUUAG/SQEN
L3          65 S L1,L2
L4          10 S L3 AND (PEPTIDE OR COMPLEX)
L5          55 S L3 NOT L4
               E OFLOXACIN/CN
L6           1 S E3
L7          32 S C18H20FN3O4/MF AND NC2NC2/ES AND 4/NR
L8          17 S L7 AND NC2OC2-NC5-C6/ES
L9          15 S L8 AND 6 CARBOXYLIC
L10         12 S L9 AND 9 FLUORO
L11          6 S L10 AND 3 METHYL 10
L12          4 S L11 AND 4 METHYL
L13          3 S L12 NOT 11C#
               E TMP/CN
               E TMPY/CN
               E TELOMERASE/CN
L14          1 S E3
               E AZT/CN
L15          1 S E4
L16         40 S C10H13N5O4/MF AND OC4/ES AND NCNC3/ES
L17         16 S L16 AND AZIDO AND THYM?
L18          6 S L17 NOT (LABELED OR (D OR T)/ELS OR 11C# OR 13C# OR 14C# OR C
               E RUBROMYCIN/CN
L19          1 S E3
               E PURPUROMYCIN/CN
L20          1 S E3
               E DIDEOXYINOSINE/CN
L21          1 S E3
               E LEVOFLOXACIN/CN
L22          1 S E3
L23        122 S C18H20FN3O4/MF
L24         17 S L23 AND NC2NC2/ES AND NC2OC2-NC5-C6/ES
L25          0 S L24 NOT L8
L26          3 S L22,L13
               E CARBOVIR/CN
L27          1 S E3
L28         21 S C11H13N5O2/MF AND C5/ES AND NCNC2-NCNC3/ES
L29          9 S L28 AND 2 AMINO 1 9 DIHYDRO
L30          7 S L29 AND 4 HYDROXYMETHYL
L31          4 S L30 NOT (T/ELS OR 14C OR 3 HYDROXYMETHYL)
               E URSODEOXYCHOLIC ACID/CN
L32          1 S E3
               E DIAZAPHILONIC ACID/CN
L33          1 S E3
               E ALTERPERYLENOL/CN
L34          1 S E3
               E 5-AZACYTIDINE/CN
L35          1 S E3
               E FOMIVIRSEN/CN
L36          1 S E3
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

```
                E DIAZAPHILONIC ACID/CN
                E 2-(3-(TRIFLUOROMETHYL)PHENYL)ISOTHIAZOLIN-3-ONE/CN
                E 3,4,9,10-PERYLENETETRACARBOXYLIC DIIMIDE/CN
L37           1 S E3
                E 10H-INDOLO(3,2-B)QUINOLINE/CN
                E 10H-INDOLO(3,2-B)-QUINOLINE/CN

     FILE 'HCAPLUS' ENTERED AT 14:43:51 ON 01 OCT 2002
                E TMPYP4
L38          31 S E3
L39          38 S 3 DEOXY 2 3 DIDEHYDROTHYMIDINE
L40           1 S 2 3 TRIFLUOROMETHYL PHENYL ISOTHIAZOLIN 3 ONE
L41          27 S TMPI
L42           7 S 10H INDOLO 3 2 B QUINOLINE
L43           0 S 2 O MERNA TELOMERASE
L44           0 S 2 O ME RNA TELOMERASE
L45          49 S 2 (S) RNA (S) TELOMERASE
L46           1 S 2 (S) O (S) ME (L) RNA (S) TELOMERASE
L47           5 S 2 (S) O (S) MERNA (S) TELOMERASE
L48           2 S 2 (S) O (S) METHYL (S) RNA (S) TELOMERASE
L49           0 S 2 (S) O (S) ALKYL (L) RNA (S) TELOMERASE
L50           0 S 2 (S) O (S) ALK (L) RNA (S) TELOMERASE
L51           6 S L46-L48
L52          46 S L45 NOT L51

     FILE 'REGISTRY' ENTERED AT 14:51:41 ON 01 OCT 2002
L53           1 S 92739-63-4
L54           1 S 38673-65-3
L55         148 S 38673-65-3/CRN
L56           1 S 3056-17-5

     FILE 'HCAPLUS' ENTERED AT 14:54:36 ON 01 OCT 2002
                SEL RN L40

     FILE 'REGISTRY' ENTERED AT 14:55:09 ON 01 OCT 2002
L57           9 S E1-E9
L58           2 S L57 AND F/ELS
L59           1 S L58 AND 220862-87-3
L60          78 S L6,L13,L53,L54,L15,L19,L20,L56,L21,L1,L22,L26,L27,L31,L59,L32

     FILE 'HCAPLUS' ENTERED AT 14:58:56 ON 01 OCT 2002
                SEL RN L42

     FILE 'REGISTRY' ENTERED AT 14:59:00 ON 01 OCT 2002
L61         155 S E10-E164
L62          70 S L61 AND 4/NR
L63           1 S L62 AND C15H10N2
L64          56 S L62 AND 10H
L65          23 S L64 NOT O/ELS
                E 4493/RID
                E 4493.57/RID
L66         609 S E3
L67         371 S L66 AND 1/NC
L68          21 S L60 NOT L1,L2
L69          22 S L68,L63

     FILE 'HCAPLUS' ENTERED AT 15:04:06 ON 01 OCT 2002
                E STYCZYNSKI P/AU
L70          19 S E3-E8
                E AHLUWALIA G/AU
L71          69 S E3,E4,E9-E11
L72          78 S L70,L71
L73        2759 S L14
```

```
L74         3490 S TELOMERASE
L75         3493 S L73,L74
L76           64 S L75 (L) INHIBIT?(S)(I OR II OR III OR IV)
L77            2 S L75 (L) INHIBIT?()(I OR II OR III OR IV)

     FILE 'REGISTRY' ENTERED AT 15:08:36 ON 01 OCT 2002
L78            1 S 354817-15-5

     FILE 'HCAPLUS' ENTERED AT 15:09:05 ON 01 OCT 2002
L79          101 S L75 (L) INHIBIT?(L) (I OR II OR III OR IV)
L80          101 S L76,L77,L79
L81          101 S L73,L74 AND L80
L82         3493 S L75,L81
L83           44 S L1 OR L2
L84           47 S L51,L83
L85        13404 S L69

     FILE 'REGISTRY' ENTERED AT 15:11:57 ON 01 OCT 2002
                SEL RN L69
L86          415 S E1-E22/CRN

     FILE 'HCAPLUS' ENTERED AT 15:12:20 ON 01 OCT 2002
L87          552 S L86
L88        17254 S L38-L52,L82-L85,L87
L89         7608 S OXFLOXACIN OR AZT OR RUBROMYCIN OR PURPUROMYCIN OR DIDEOXYINO
L90           29 S FOMIVIRSEN OR CATION?(L)PROPHYRIN?
L91         2408 S ZIDOVUDINE
L92        19972 S L88-L91
L93           12 S L92 AND L72
                E HAIR/CT
                E E3+ALL
L94        12678 S E6,E5
L95         8391 S E10-E14
                E E17+ALL
L96        13115 S E2
                E E9+ALL
                E E15+ALL
L97         1847 S E4
                E E7+ALL
                E E17+ALL
L98         6514 S E6,E7
                E E9+ALL
                E E19+ALL
L99          712 S E2
L100          29 S L72 AND L94-L99
L101          29 S L72 AND HAIR
L102          29 S L100,L101
L103           0 S L102 AND L93
L104           0 S L102 AND ?TELOMERAS?
L105          46 S L92 AND L94-L99
L106          54 S L92 AND HAIR
L107          63 S L105,L106
L108          45 S L107 AND (1 OR 62 OR 63)/SC,SX
L109          18 S L107 NOT L108
                SEL DN AN L108 14 15 26 36 38 44 45
L110           7 S L108 AND E1-E21

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:40:43 ON 01 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Oct 2002 VOL 137 ISS 14
FILE LAST UPDATED: 30 Sep 2002 (20020930/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d l110 all hitstr tot

L110 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2002 ACS
AN **2000:117139** HCAPLUS
DN **132:177442**
TI Assembly of **telomerase** components and chaperonins and methods and compositions for inhibiting or stimulating **telomerase** assembly
IN White, Michael A.
PA Geron Corporation, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N009-12
ICS C12Q001-48; G01N033-573; G01N033-50; A61K038-45
CC 7-5 (Enzymes)
Section cross-reference(s): **63**
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000008135	A1	20000217	WO 1999-US17724	19990805
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9953381	A1	20000228	AU 1999-53381	19990805
PRAI	US 1998-95976P	P	19980809		
	WO 1999-US17724	W	19990805		

AB Methods and compns. for assembling active **telomerase** in vitro and in cells, be they in culture or in vivo , are provided, as are methods and compns. for inhibiting or enhancing **telomerase** activity through modulation of **telomerase** assembly. In certain preferred embodiments, methods are provided for the in vitro assembly of a **telomerase** protein component and a **telomerase** RNA component, wherein the methods involve the addn. of one or more chaperonin

mols., particularly substantially purified or recombinant **telomerase** chaperonins, which include the proteins hsp40, hsp70, hsp90, p23 and HOP. In such methods, one or more **telomerase** chaperonins are combined in a reaction mixt. that also comprises the catalytic protein and RNA components of **telomerase**. This invention is based on the discovery that phosphoprotein p23 interacts and promotes assembly of **telomerase** activity, and that the hsp90 inhibitor geldanamycin blocks the enhancement of **telomerase** reconstitution. **Telomerase** activity is also enhanced by addn. of heat-shock proteins 40 and 70 as well as by HOP (heat shock protein organizing protein). Screening methods for identifying **telomerase** assembly and activity inhibitors are also provided, along with methods for stimulating or inhibiting **telomerase** activity and assembly.

ST **telomerase** assembly reverse transcriptase RNA chaperonin; drug design screening **telomerase** assembly assay

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(HOP (heat-shock protein-organizing protein); assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(HSP 70; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(HSP 90; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Animal cell line
(HT-1080; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Nervous system
(Huntington's chorea, treatment of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Animal cell
Anti-Alzheimer's agents
Anti-infective agents
Antiparkinsonian agents
Antitumor agents
Bird (Aves)
Cat (Felis catus)
Cattle
Dog (Canis familiaris)
Drug screening
Drugs
Gene therapy
Horse (Equus caballus)
Molecular association
Sheep
Swine
Vertebrate (Vertebrata)
(assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Antisense oligonucleotides
Ribozymes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Joint, anatomical
(degeneration, treatment of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Blood vessel
(endothelium, treatment of conditions assocd. with replicative capacity of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT **Hair**
(follicle, treatment of conditions assocd. with replicative capacity of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(hsp 40; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Antitumor agents
(leukemia; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Eye, disease
(macula, degeneration, treatment of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Cell proliferation
(modulating disorders of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Hematopoietic precursor cell
Lymphocyte
(natural killer cell, treatment of conditions assocd. with replicative capacity of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Bone marrow
(osteoprogenitor cell, treatment of conditions assocd. with replicative capacity of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Eye
(pigment epithelium, treatment of conditions assocd. with replicative capacity of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Brain, disease
(stroke, treatment of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT Chaperonins
RNA
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**telomerase** component; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)

IT B cell (lymphocyte)
Basophil
Chondrocyte
Fibroblast
Monocyte
Neutrophil
Osteoblast
T cell (lymphocyte)
(treatment of conditions assocd. with replicative capacity of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)
IT **Alopecia**
Cell aging
(treatment of; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)
IT 30562-34-6, Geldanamycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)
IT **120178-12-3, Telomerase** reverse transcriptase
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)
IT 197183-99-6 243940-92-3, 4: PN: WO0008135 SEQID: 6 unclaimed DNA 243940-93-4, 3: PN: WO0008135 SEQID: 5 unclaimed DNA 259238-19-2, 2: PN: WO0008135 SEQID: 4 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Univ California; WO 9801542 A 1998 HCAPLUS
(2) Weinrich; NATURE GENETICS 1997, V17, P498 HCAPLUS
IT **120178-12-3, Telomerase** reverse transcriptase
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(assembly of **telomerase** components and chaperonins and methods and compns. for inhibiting or stimulating **telomerase** assembly)
RN 120178-12-3 HCAPLUS
CN Nucleotidyltransferase, terminal deoxyribo- (telomeric DNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L110 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2002 ACS
AN **2000:83232** HCAPLUS
DN **132:127477**
TI Cosmetic and dermatological preparations with an effective content of bile acids, their salts or derivatives
IN Schreiner, Volker; Lanzendoerfer, Ghita
PA Beiersdorf A.-G., Germany
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM A61K007-48

ICS A61K007-50; A61K007-027; A61K007-32; A61K007-075
CC **62-4** (Essential Oils and Cosmetics)
Section cross-reference(s): **63**
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19834814	A1	20000203	DE 1998-19834814	19980801
	WO 2000007557	A1	20000217	WO 1999-EP5157	19990720
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1100455	A1	20010523	EP 1999-938295	19990720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	DE 1998-19834814	A	19980801		
	WO 1999-EP5157	W	19990720		

AB Topical application of prepns. contg. bile acids, their salts and/or derivs. restores or reinforces the barrier function of the skin, counteracts skin drying and aging, and protects the skin from environmental influences. Thus, a gel contained sucrose stearate 3.00, cetearyl alc. 2.00, deoxycholic acid 0.02, Carbopol 0.50, glycerin 3.00, antioxidants, preservatives, neutralizing agents, perfume, dyes, and H2O to 100 wt.%.

ST skin barrier bile acid salt; deoxycholate skin drying

IT Cosmetics
(barrier creams; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Cosmetics
(barrier gels; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Cosmetics
Hair preparations
(conditioners; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT **Shampoos**
(conditioning; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Bile acids
Bile salts
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Cosmetics
Drug delivery systems
(emulsions; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Drug delivery systems
(gels; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Cosmetics
(lipsticks; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Cosmetics
Drug delivery systems
(lotions; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Cosmetics
(makeups; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Bath preparations
(oils; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)

IT Cosmetics
Drug delivery systems
(oily; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
IT Drug delivery systems
(ointments, creams; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
IT Drug delivery systems
(ointments; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
IT Antiperspirants
(roll-on; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
IT Cosmetics
Drug delivery systems
(sprays; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
IT Drug delivery systems
(topical; cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
IT 81-23-2, Dehydrocholic acid 81-24-3, Taurocholic acid 83-44-3, Deoxycholic acid **128-13-2**, Ursodeoxycholic acid 434-13-9, Lithocholic acid 475-31-0, Glycocholic acid 516-50-7, Taurodeoxycholic acid 516-90-5, Taurolithocholic acid
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
IT **128-13-2**, Ursodeoxycholic acid
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic and dermatol. prepns. contg. bile acids, their salts or derivs.)
RN 128-13-2 HCAPLUS
CN Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L110 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2002 ACS
AN **1998:274854** HCAPLUS
DN **129:27504**
TI Secretion stimulants and oral compositions containing bile acid
IN Kosuga, Masanori; Kosuga, Takuo; Fukushima, Makoto; Inaoka, Yasunori; Okuda, Takehiro
PA Doctor's Cosmetics Y. K., Japan; Pola Chemical Industries, Inc.
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

DT Patent
LA Japanese
IC ICM A61K035-413
ICS A23L001-30; A61K007-06; A61K031-575
CC 18-5 (Animal Nutrition)
Section cross-reference(s): 1, 17, 62
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10114665	A2	19980506	JP 1996-272724	19961015

AB Title stimulants, useful for foods and pharmaceuticals, contain bile acid and/or its salts. The stimulants show skin conditioning effect, treatment of skin diseases, and stimulation of **hair** growth, digestive juice secretion, sweating, defecation, and urination.
ST secretion stimulant oral bile acid; food secretion stimulant bile acid; pharmaceutical secretion stimulant bile acid
IT Dermatitis
(atopic, treatment; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Skin, disease
(dermatomycosis, treatment; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Skin, disease
(dry, treatment; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT **Hair**
(growth stimulation; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Skin, disease
Skin, disease
(injury, treatment; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Drug delivery systems
(oral; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Skin, disease
(pigmentation, treatment; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Candy
Defecation
Digestive juice
Micturition
Secretion (process)
Sweat
(secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Bile acids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT Dermatitis
Keratosis
Psoriasis
Wart
(treatment; secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT 81-25-4, Cholic acid 145-41-5, Sodium dehydrocholate 145-42-6, Sodium taurocholate 302-95-4, Sodium deoxycholate 361-09-1, Sodium cholate 863-57-0, Sodium glycocholate 1180-95-6, Sodium taurodeoxycholate 2646-38-0, Sodium chenodeoxycholate **2898-95-5**, Sodium ursodeoxycholate 6009-98-9, Sodium taurochenodeoxycholate 13284-86-1, Sodium lithocholate 16409-34-0, Sodium glycodeoxycholate 16564-43-5, Sodium glycochenodeoxycholate 24404-83-9, Sodium glycolithocholate

41945-48-6 89314-78-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretion stimulants contg. bile acids for foods and pharmaceuticals)
IT **2898-95-5**, Sodium ursodeoxycholate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretion stimulants contg. bile acids for foods and pharmaceuticals)
RN 2898-95-5 HCAPLUS
CN Cholan-24-oic acid, 3,7-dihydroxy-, monosodium salt, (3.alpha.,5.beta.,7.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L110 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2002 ACS
AN **1993:633699** HCAPLUS
DN **119:233699**
TI **Hair** preparations containing levodopa
IN Rizzo, Antonio
PA Spain
SO Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K007-06
ICS B05C009-04
CC **62-3** (Essential Oils and Cosmetics)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 565010	A1	19931013	EP 1993-105555	19930403
R: DE, ES, FR				
PRAI IT 1992-PN30		19920410		

AB **Hair** prepns. for stimulation of new **hair** growth, reinvigoration of existing **hair**, and promotion of **hair** repigmentation, comprises levodopa as an active substance and further contains a phosphoric acid salt to strengthen the activation of the local microcirculation, a decarboxylase inhibitor to prevent the compn. from spoiling, and a deoxycholic acid to remove the excess of scalp sebum. A **hair** lotion contg. levodopa 2.5, creatine phosphate 0.5, ursodeoxycholic acid 0.6, ascorbic acid 0.12g, fragrance q.s., and EtOH/water to 100 mL., is claimed.

ST **hair** tonic levodopa phosphate deoxycholate ascorbate
IT **Hair preparations**
(lotions, levodopa and creatine phosphate and ascorbate and ursodeoxycholate in)
IT **Hair preparations**
(tonics, levodopa and creatine phosphate and ascorbate and ursodeoxycholate in)
IT 59-92-7, Levodopa, biological studies
RL: BIOL (Biological study)
(**hair** tonics contg.)
IT 50-81-7, L-Ascorbic acid, biological studies 67-07-2, Creatine phosphate 83-44-3D, Deoxycholic acid, derivs. **128-13-2**, Ursodeoxycholic acid 7664-38-2D, Phosphoric acid, salts
RL: BIOL (Biological study)
(**hair** tonics contg. levodopa and)
IT 9027-22-9, Decarboxylase
RL: USES (Uses)
(inhibitors, **hair** tonics contg. levodopa and)
IT **128-13-2**, Ursodeoxycholic acid
RL: BIOL (Biological study)
(**hair** tonics contg. levodopa and)
RN 128-13-2 HCAPLUS
CN Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L110 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2002 ACS
AN **1993:97315** HCAPLUS
DN **118:97315**
TI Analysis of ofloxacin in **hair** as a measure of **hair** growth and as a time marker for **hair** analysis
AU Miyazawa, Norio; Uematsu, Toshihiko
CS Sch. Med., Hamamatsu Univ., Hamamatsu, 431-31, Japan
SO Therapeutic Drug Monitoring (1992), 14(6), 525-8
CODEN: TDMODV; ISSN: 0163-4356
DT Journal
LA English
CC 9-3 (Biochemical Methods)
Section cross-reference(s): **1**, 4, 13
AB The distribution of ofloxacin (OFLX) along a single **hair** shaft was analyzed in detail for use as an index of **hair** growth and as a time marker for drug anal. in air. A single **hair** obtained from each of seven subjects, who had taken OFLX for 1-4 days (total of 200-1200 mg) 2.7-5.3 mo before **hair** sampling, was cut into 1-cm-long portions successively from its scalp end. OFLX in each **hair** portion was measured by high-performance liq. chromatog. with a fluorescence detector, and the distance from the scalp end of the

hair portion contg. OFLX was detd. Then the other 2-cm long segment of **hair**, which had the above-detd. distance at its middle, was cut successively into 2-mm-long pieces and OFLX was detd. in each piece. This procedure was repeated in a total of three to four **hair** strands collected from one subject. OFLX was obsd. to distribute only in one to three consecutive 2-mm-long pieces of **hair**, showing no large diffusion of OFLX along the **hair** shaft with time. Therefore, OFLX distribution may serve as a time marker for analyzing other drugs in **hair**. **Hair** growth rate could be thus estd. and ranged from 0.99 to 1.27 cm/mo (1.12 .+-. 0.11 cm/mo, mean .+-. SD) among individuals. The intraindividual variability of **hair** growth rate was 4.8-18.1% (10.3 .+-. 5.1%) as coeff. of variation.

ST ofloxacin detn chromatog **hair** growth; liq chromatog ofloxacin **hair** growth

IT **Hair**
(of ofloxacin detn. in, by HPLC in human, as growth marker)

IT **82419-36-1**, Ofloxacin
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, by HPLC human, as **hair** growth rate marker)

IT **82419-36-1**, Ofloxacin
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, by HPLC human, as **hair** growth rate marker)

RN 82419-36-1 HCAPLUS

CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- (9CI) (CA INDEX NAME)



L110 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2002 ACS

AN **1981:127147** HCAPLUS

DN **94:127147**

TI Cosmetic agent for treating the **hair** and scalp

PA Also Laboratori S.a.S. Dr. P. Sorbini e Co., Italy

SO Austrian, 5 pp.
CODEN: AUXXAK

DT Patent

LA German

IC A61K007-06

CC **62-3** (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AT 360160	B	19801229	AT 1978-4522	19780621
	AT 7804522	A	19800515		

AB A cosmetic for treating the **hair** and scalp to reduce scaling and **hair** loss contains 0.6-1% by wt. chenodeoxycholic acid [474-25-9] or ursodeoxycholic acid [**128-13-2**], or their salts or derivs. and 0.1-0.25% by wt. retinoic acid [302-79-4]. The prepn. has a pH of approx. 6, and has a base contg. glycerol, propylene glycol, and (or)

EtOH, with other optional ingredients.
ST bile acid retinoate scalp **hair**; dandruff bile acid retinoate; alopecia bile acid retinoate
IT **Alopecia**
Dandruff
(bile acids and retinoic acid prepn. for control of)
IT 302-79-4
RL: BIOL (Biological study)
(**hair** and scalp prepn. contg. bile acids and)
IT **128-13-2** 474-25-9
RL: BIOL (Biological study)
(**hair** and scalp prepn. contg. retinoic acid and)
IT **128-13-2**
RL: BIOL (Biological study)
(**hair** and scalp prepn. contg. retinoic acid and)
RN 128-13-2 HCAPLUS
CN Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L110 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2002 ACS
AN **1978:494892** HCAPLUS
DN **89:94892**
TI Chemical composition for treatment of the scalp to prevent falling **hair**
IN Sorbini, Paolo
PA Also Laboratori S.a.S. Dr. P. Sorbini e Co., Italy
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
IC A61K007-06
CC **62-3** (Essential Oils and Cosmetics)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2758484	A1	19780706	DE 1977-2758484	19771228
	DE 2758484	C2	19870129		
	FR 2375859	A1	19780728	FR 1978-2	19780102
	FR 2375859	B1	19830729		
	GB 1560461	A	19800206	GB 1978-63	19780103
	US 4185099	A	19800122	US 1978-868563	19780110
	CH 636265	A	19830531	CH 1978-6949	19780626
	AU 528334	B2	19830428	AU 1978-37488	19780627
	AU 7837488	A1	19800103		
	CA 1106287	A1	19810804	CA 1978-306632	19780630
	JP 63001282	B4	19880112	JP 1978-80693	19780703

JP 55009007 A2 19800122
PRAI IT 1977-19025 19770104
AB Compns. for treatment of the scalp to prevent **hair** loss contain 0.6-1% of a natural surfactant, such as a bile acid, which acts preferentially on fats and esp. on cholesterol, 0.10-0.25% of a cell proliferation regulator such as retinoic acid [302-79-4] or provitamin A, and vehicles or other optional ingredients. For example, a compn. contained retinoic acid 0.10, chenodeoxycholic acid [474-25-9] 0.70, nicotinamide 0.20, vitamin H1 0.10, glycerol 30 and propylene glycol 30 g with alc. to give 100 g.
ST **hair** loss bile acid compn; scalp conditioner bile acid; chenodeoxycholate scalp conditioner; retinoate chenodeoxycholate **hair** loss; ursodeoxycholate scalp **hair** loss
IT Scalp
(bile acids compns. for treatment of, for **hair** loss prevention)
IT **Hair preparations**
(for **hair** loss prevention, bile acids in)
IT Bile acids
RL: BIOL (Biological study)
(**hair** loss-preventing compns. contg.)
IT **128-13-2** 302-79-4 474-25-9
RL: BIOL (Biological study)
(**hair** loss-preventing compns. contg.)
IT **128-13-2**
RL: BIOL (Biological study)
(**hair** loss-preventing compns. contg.)
RN 128-13-2 HCAPLUS
CN Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> sel hit rn 1110
E22 THROUGH E25 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:41:05 ON 01 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2002 HIGHEST RN 457600-76-9
DICTIONARY FILE UPDATES: 30 SEP 2002 HIGHEST RN 457600-76-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

```
=> s e22-e25
             1 128-13-2/BI
               (128-13-2/RN)
             1 120178-12-3/BI
               (120178-12-3/RN)
             1 2898-95-5/BI
               (2898-95-5/RN)
             1 82419-36-1/BI
               (82419-36-1/RN)
L111         4 (128-13-2/BI OR 120178-12-3/BI OR 2898-95-5/BI OR 82419-36-1/BI)

=> d ide can tot

L111 ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2002 ACS
RN   120178-12-3  REGISTRY
CN   Nucleotidyltransferase, terminal deoxyribo- (telomeric DNA) (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   DNA telomerase
CN   Subunit (Mesocricetus auratus)
CN   Telomerase
CN   Telomerase reverse transcriptase
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CAPLUS,
       CBNB, CEN, CIN, IPA, PROMT, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
            2742 REFERENCES IN FILE CA (1962 TO DATE)
               6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            2758 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE   1:  137:201341

REFERENCE   2:  137:200246

REFERENCE   3:  137:199716

REFERENCE   4:  137:199490

REFERENCE   5:  137:199185

REFERENCE   6:  137:199168

REFERENCE   7:  137:199146

REFERENCE   8:  137:199141

REFERENCE   9:  137:199139
```

REFERENCE 10: 137:198909

L111 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2002 ACS
RN **82419-36-1** REGISTRY
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (.+-.)-
OTHER NAMES:
CN (.+-.)-Ofloxacin
CN 9-Fluoro-2,3-dihydro-3-methyl-10-(N-methylpiperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
CN 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
CN DL 8280
CN Floxal
CN Floxin
CN HOE 280
CN Ocuflox
CN Oflox
CN Ofloxacin
CN Ofloxacine
CN ORF 18489
CN PT 01
CN Tarivid
CN Visiren
FS 3D CONCORD
DR 85344-55-4, 83380-47-6, 86784-41-0, 303013-04-9
MF C18 H20 F N3 O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIUDB, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3423 REFERENCES IN FILE CA (1962 TO DATE)
31 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3431 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:206549

REFERENCE 2: 137:194931

REFERENCE 3: 137:190519

REFERENCE 4: 137:182205

REFERENCE 5: 137:182192

REFERENCE 6: 137:179068

REFERENCE 7: 137:169369

REFERENCE 8: 137:166083

REFERENCE 9: 137:166058

REFERENCE 10: 137:152231

L111 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2002 ACS
RN **2898-95-5** REGISTRY
CN Cholan-24-oic acid, 3,7-dihydroxy-, monosodium salt, (3.alpha.,5.beta.,7.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5.beta.-Cholan-24-oic acid, 3.alpha.,7.beta.-dihydroxy-, monosodium salt (8CI)
CN Ursodeoxycholic acid, sodium salt (6CI)
OTHER NAMES:
CN Sodium ursodeoxycholate
CN Sodium ursodesoxycholate
FS STEREOSEARCH
MF C24 H40 O4 . Na
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, EMBASE, IPA, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
CRN (128-13-2)

Absolute stereochemistry.



● Na

112 REFERENCES IN FILE CA (1962 TO DATE)
112 REFERENCES IN FILE CAPLUS (1962 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:201494

REFERENCE 2: 137:59261

REFERENCE 3: 137:59260

REFERENCE 4: 137:37671

REFERENCE 5: 137:2216

REFERENCE 6: 135:362564

REFERENCE 7: 135:262268

REFERENCE 8: 134:198075

REFERENCE 9: 134:159863

REFERENCE 10: 134:141115

L111 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2002 ACS
RN **128-13-2** REGISTRY
CN Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5.beta.-Cholan-24-oic acid, 3.alpha.,7.beta.-dihydroxy- (8CI)
OTHER NAMES:
CN 17.beta.-(1-Methyl-3-carboxypropyl)etiocholane-3.alpha.,7.beta.-diol
CN 3.alpha.,7.beta.-Dihydroxy-5.beta.-cholan-24-oate
CN 3.alpha.,7.beta.-Dihydroxy-5.beta.-cholan-24-oic acid
CN 3.alpha.,7.beta.-Dihydroxy-5.beta.-cholanic acid
CN 3.alpha.,7.beta.-Dihydroxy-5.beta.-cholanoic acid
CN 3.alpha.,7.beta.-Dihydroxycholanic acid
CN 7.beta.-Hydroxylithocholic acid
CN Actigall
CN Desocol
CN Deursil
CN Urso
CN Ursocholic acid, deoxy-
CN Ursodeoxycholic acid
CN Ursodesoxycholic acid
CN Ursodiol
CN Ursofalk
FS STEREOSEARCH
DR 50809-41-1, 80225-86-1
MF C24 H40 O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2246 REFERENCES IN FILE CA (1962 TO DATE)
89 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2251 REFERENCES IN FILE CAPLUS (1962 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:199415

REFERENCE 2: 137:198847

REFERENCE 3: 137:195488

REFERENCE 4: 137:194756

REFERENCE 5: 137:190734

REFERENCE 6: 137:179879

REFERENCE 7: 137:179497

REFERENCE 8: 137:174947

REFERENCE 9: 137:167116

REFERENCE 10: 137:163654

=> s l69 not l111
L112 20 L69 NOT L111

=> d ide can tot

L112 ANSWER 1 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 230287-51-1 REGISTRY
CN 1H-Dibenzo[b,d]pyran-2,3-dicarboxylic acid, 8-[(2,4-dihydroxy-6-methylbenzoyl)oxy]-1-[7-[(2,4-dihydroxy-6-methylbenzoyl)oxy]-7,8-dihydro-7-methyl-6,8-dioxo-6H-2-benzopyran-3-yl]-2,3,4,7,8,9-hexahydro-8-methyl-7,9-dioxo- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Diazaphilonic acid**
CN PF 1195
FS STEREOSEARCH
MF C42 H32 O18
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Rotation (-).
Currently available stereo shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 131:242086

REFERENCE 2: 131:85211

L112 ANSWER 2 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN **220862-87-3** REGISTRY
CN 3(2H)-Isothiazolone, 2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C10 H6 F3 N O S**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 131:281096

REFERENCE 2: 130:205115

L112 ANSWER 3 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 172720-96-6 REGISTRY
CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-, trans- (9CI)** (CA INDEX NAME)
FS STEREOSEARCH

MF **C11 H13 N5 O2**
SR CA
LC STN Files: CA, CAPLUS

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:87664

L112 ANSWER 4 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 144245-52-3 REGISTRY
CN DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Deoxyribonucleic acid, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G)
OTHER NAMES:
CN **Fomivirsen**
CN ISIS 2922
FS NUCLEIC ACID SEQUENCE
MF C204 H263 N63 O114 P20 S20
CI MAN
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CEN, CIN, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, MRCK*, PROMT, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
35 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
36 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:240875

REFERENCE 2: 136:31314

REFERENCE 3: 136:14923

REFERENCE 4: 135:297927

REFERENCE 5: 134:261230

REFERENCE 6: 134:212581

REFERENCE 7: 134:25338

REFERENCE 8: 133:198688

REFERENCE 9: 133:114462

REFERENCE 10: 133:26363

L112 ANSWER 5 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 124915-24-8 REGISTRY
CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,4R)-4-(hydroxymethyl)-2-cyclopenten-1-yl]- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-, (1S-cis)-**
OTHER NAMES:
CN (+)-Carbovir
FS STEREOSEARCH
MF **C11 H13 N5 O2**
SR CA
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMINFORMRX, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19 REFERENCES IN FILE CA (1962 TO DATE)
19 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:334705

REFERENCE 2: 131:199928

REFERENCE 3: 125:75411

REFERENCE 4: 124:9286

REFERENCE 5: 123:144465

REFERENCE 6: 121:301209

REFERENCE 7: 121:83824

REFERENCE 8: 118:51800

REFERENCE 9: 117:245031

REFERENCE 10: 117:244983

L112 ANSWER 6 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 120443-30-3 REGISTRY
CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1R,4S)-4-(hydroxymethyl)-2-cyclopenten-1-yl]- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-, (1R-cis)-**
OTHER NAMES:
CN (-)-Carbovir
FS STEREOSEARCH
MF **C11 H13 N5 O2**
CI COM
SR CAS Registry Services
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CHEMINFORMRX, IPA, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

77 REFERENCES IN FILE CA (1962 TO DATE)
77 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:167567

REFERENCE 2: 136:79728

REFERENCE 3: 135:13822

REFERENCE 4: 134:147790

REFERENCE 5: 134:110094

REFERENCE 6: 133:358877

REFERENCE 7: 133:193401

REFERENCE 8: 132:342742

REFERENCE 9: 132:237372

REFERENCE 10: 131:266562

L112 ANSWER 7 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 118353-05-2 REGISTRY
CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1R,4S)-4-(hydroxymethyl)-2-cyclopenten-1-yl]-, rel- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-, cis-(.+-.)-**
OTHER NAMES:
CN (.+-.)-Carbovir
CN **6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-, cis-**
CN **Carbovir**
CN GR 90352X
CN NSC 614846
FS STEREOSEARCH
DR 124915-20-4
MF **C11 H13 N5 O2**
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMINFORMRX, CIN, DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

71 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
71 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:109438

REFERENCE 2: 137:93918

REFERENCE 3: 137:338

REFERENCE 4: 136:241028

REFERENCE 5: 136:144720

REFERENCE 6: 134:42012

REFERENCE 7: 133:213270

REFERENCE 8: 133:144278

REFERENCE 9: 133:129845

REFERENCE 10: 133:79174

L112 ANSWER 8 OF 20 REGISTRY COPYRIGHT 2002 ACS

RN 100986-86-5 REGISTRY
CN **7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3R)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (R)-**
OTHER NAMES:
CN (+)-Ofloxacin
CN (R)-(+)-Ofloxacin
CN (R)-Ofloxacin
CN D-Ofloxacin
CN DR 3354
FS STEREOSEARCH
MF **C18 H20 F N3 O4**
SR CA
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, DRUGPAT, DRUGUPDATES, IPA, PHAR, PROMT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

93 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
93 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:130018

REFERENCE 2: 136:226281

REFERENCE 3: 136:97972

REFERENCE 4: 136:91055

REFERENCE 5: 136:63603

REFERENCE 6: 136:50920

REFERENCE 7: 135:376911

REFERENCE 8: 135:146729

REFERENCE 9: 135:101838

REFERENCE 10: 134:198177

L112 ANSWER 9 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 100986-85-4 REGISTRY
CN **7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-**
OTHER NAMES:
CN (-)-Ofloxacin
CN (S)-(-)-Ofloxacin
CN (S)-Ofloxacin
CN Cravit
CN DR 3355
CN HR 355
CN Levaquin
CN **Levofloxacin**
CN RWJ 25213-097
CN Tavanic
FS STEREOSEARCH
MF **C18 H20 F N3 O4**
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1355 REFERENCES IN FILE CA (1962 TO DATE)
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1373 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:198160

REFERENCE 2: 137:195042

REFERENCE 3: 137:182202

REFERENCE 4: 137:182198

REFERENCE 5: 137:182196

REFERENCE 6: 137:182195

REFERENCE 7: 137:182194

REFERENCE 8: 137:182192

REFERENCE 9: 137:182176

REFERENCE 10: 137:179415

L112 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN **92739-63-4** REGISTRY
CN Pyridinium, 4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis[1-methyl-, tetrachloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5,10,15,20-Tetrakis(1-methylpyridinium-4-yl)porphyrin tetrachloride
MF C44 H38 N8 . 4 Cl
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, GMELIN*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
CRN (38673-65-3)



51 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
51 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:162961

REFERENCE 2: 137:29891

REFERENCE 3: 136:294662

REFERENCE 4: 136:151025

REFERENCE 5: 135:327088

REFERENCE 6: 135:253342

REFERENCE 7: 134:366729

REFERENCE 8: 133:366681

REFERENCE 9: 133:237731

REFERENCE 10: 133:199251

L112 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 88899-62-1 REGISTRY
CN 3,10-Perylenedione, 1,2,12a,12b-tetrahydro-1,4,9,12a-tetrahydroxy-, (1S,12aR,12bS)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3,10-Perylenedione, 1,2,12a,12b-tetrahydro-1,4,9,12a-tetrahydroxy-, [1S-(1.alpha.,12a.beta.,12b.alpha.)]-
OTHER NAMES:
CN (+)-Alterperylenol
CN Alteichin
CN **Alterperylenol**
FS STEREOSEARCH
DR 95781-70-7
MF C20 H14 O6
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, MEDLINE, NAPRALERT, TOXCENTER
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 131:39337

REFERENCE 2: 110:208999

REFERENCE 3: 110:151002

REFERENCE 4: 100:82450

L112 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 69655-05-6 REGISTRY
CN Inosine, 2',3'-dideoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 2',3'-Dideoxyinosine
CN 876: PN: WO02055741 SEQID: 891 claimed sequence
CN BMY 40900
CN DdI
CN DdI (nucleoside)
CN Didanosine
CN **Dideoxyinosine**
CN NSC 612049
CN Videx
FS STEREOSEARCH
MF C10 H12 N4 O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1540 REFERENCES IN FILE CA (1962 TO DATE)
31 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1551 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:206546

REFERENCE 2: 137:195069

REFERENCE 3: 137:195066

REFERENCE 4: 137:195065

REFERENCE 5: 137:195060

REFERENCE 6: 137:195052

REFERENCE 7: 137:195021

REFERENCE 8: 137:195020

REFERENCE 9: 137:190521

REFERENCE 10: 137:179859

L112 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 53969-01-0 REGISTRY
CN Spiro[benzo[1,2-b:5,4-c']dipyran-2(3H),2'(3'H)-naphtho[2,3-b]furan]-7-carboxylic acid, 4,5',8',9-tetrahydro-4,4',9',10-tetrahydroxy-7'-methoxy-5',8',9-trioxo-, methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Purpuromycin**
DR 56324-34-6
MF C26 H18 O13
CI COM
LC STN Files: ADISINSIGHT, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, PHAR, RTECS*, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
22 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:150218

REFERENCE 2: 135:266637

REFERENCE 3: 134:242688

REFERENCE 4: 133:53163

REFERENCE 5: 129:202782

REFERENCE 6: 127:231797

REFERENCE 7: 126:157311

REFERENCE 8: 125:275480

REFERENCE 9: 124:170381

REFERENCE 10: 120:8408

L112 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN **38673-65-3** REGISTRY
CN Pyridinium, 4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis[1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5,10,15,20-Tetrakis(1-methyl-4-pyridyl)porphyrin

CN 5,10,15,20-Tetrakis(1-methylpyridinium-4-yl)porphyrin
CN 5,10,15,20-Tetrakis(N-methyl-4-pyridyl)porphine
CN 5,10,15,20-Tetrakis(N-methylpyridinium-4-yl)-21H,23H-porphine
CN meso-Tetra(N-methyl-4-pyridyl)porphine(4+)
CN meso-Tetrakis(4-N-methylpyridiniumyl)porphyrin
CN meso-Tetrakis(N-methyl-4-pyridiniumyl)porphine
CN meso-Tetrakis(N-methyl-4-pyridyl)porphine
CN meso-Tetrakis(N-methylpyridinium-4-yl)porphyrin
CN Tetra(N-methylpyridinium-4-yl)porphine
CN Tetrakis(4-N-methylpyridyl)porphine
DR 139290-19-0, 82358-79-0
MF C44 H38 N8
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CANCERLIT, CAPLUS, CHEMCATS, GMELIN*, MEDLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



373 REFERENCES IN FILE CA (1962 TO DATE)
63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
373 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:162961

REFERENCE 2: 137:154661

REFERENCE 3: 137:130228

REFERENCE 4: 137:105827

REFERENCE 5: 137:105820

REFERENCE 6: 137:70433

REFERENCE 7: 137:70142

REFERENCE 8: 137:17200

REFERENCE 9: 137:191

REFERENCE 10: 136:334154

L112 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 30516-87-1 REGISTRY
CN Thymidine, 3'-azido-3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3'-Azido-3'-deoxythymidine
CN 3'-Azidothymidine
CN 3'-Deoxy-3'-azidothymidine
CN 874: PN: WO02055741 SEQID: 889 claimed sequence
CN Azidothymidine
CN Azitidin
CN AZT
CN **AZT (pharmaceutical)**
CN BW-A 509U
CN NSC 602670
CN Retrovir
CN Retrovir IV
CN Timazid
CN ZDV
CN Zidovudine
FS STEREOSEARCH
DR 399024-19-2
MF C10 H13 N5 O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4114 REFERENCES IN FILE CA (1962 TO DATE)
164 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4132 REFERENCES IN FILE CAPLUS (1962 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:206546

REFERENCE 2: 137:206521

REFERENCE 3: 137:195071

REFERENCE 4: 137:195069

REFERENCE 5: 137:195068

REFERENCE 6: 137:195067

REFERENCE 7: 137:195066

REFERENCE 8: 137:195065

REFERENCE 9: 137:195060

REFERENCE 10: 137:195052

L112 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN **3056-17-5** REGISTRY
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2'-Thymidinene, 3'-deoxy- (8CI)
CN Thymine, 1-(2,3-dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)- (7CI, 8CI)
OTHER NAMES:
CN 2',3'-Didehydro-3'-deoxythymidine
CN 3'-Deoxy-2',3'-didehydrothymidine
CN 879: PN: WO02055741 SEQID: 894 claimed sequence
CN BMY 27857
CN D 4T
CN D 4T (nucleoside)
CN Sanilvudine
CN Stavudine
CN Zerit
FS STEREOSEARCH
DR 132425-31-1
MF C10 H12 N2 O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1132 REFERENCES IN FILE CA (1962 TO DATE)
30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1145 REFERENCES IN FILE CAPLUS (1962 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:199994

REFERENCE 2: 137:195071

REFERENCE 3: 137:195069

REFERENCE 4: 137:195065

REFERENCE 5: 137:195060

REFERENCE 6: 137:195052

REFERENCE 7: 137:195021

REFERENCE 8: 137:195020

REFERENCE 9: 137:179354

REFERENCE 10: 137:179352

L112 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 1393-16-4 REGISTRY
CN **Rubromycin (8CI)** (CA INDEX NAME)
MF Unspecified
CI MAN
LC STN Files: BIOSIS, EMBASE, RTECS*, TOXCENTER
(*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L112 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 320-67-2 REGISTRY
CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN s-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl- (8CI)
OTHER NAMES:
CN 18: PN: WO0148150 SEQID: 33 claimed sequence
CN **5-Azacytidine**
CN Antibiotic U 18496
CN Azacitidine
CN Azacytidine
CN NSC 102816
CN NSC 103-627
CN U 18496
FS STEREOSEARCH
DR 292869-98-8
MF C8 H12 N4 O5
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1181 REFERENCES IN FILE CA (1962 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1182 REFERENCES IN FILE CAPLUS (1962 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:195104

REFERENCE 2: 137:149661

REFERENCE 3: 137:149551

REFERENCE 4: 137:119122

REFERENCE 5: 137:106328

REFERENCE 6: 137:104801

REFERENCE 7: 137:103510

REFERENCE 8: 137:103184

REFERENCE 9: 137:88442

REFERENCE 10: 137:57593

L112 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN **243-58-3** REGISTRY
CN 10H-Quindoline (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Quindoline (7CI, 8CI)
OTHER NAMES:
CN Norcryptolepine
FS 3D CONCORD
MF **C15 H10 N2**
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, IPA, MEDLINE, NAPRALERT, PIRA, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

30 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
30 REFERENCES IN FILE CAPLUS (1962 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:63084

REFERENCE 2: 137:30439

REFERENCE 3: 135:318603

REFERENCE 4: 134:295759

REFERENCE 5: 134:5064

REFERENCE 6: 133:246808

REFERENCE 7: 132:227241

REFERENCE 8: 131:351518

REFERENCE 9: 131:199864

REFERENCE 10: 131:32082

L112 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2002 ACS
RN 81-33-4 REGISTRY
CN Anthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline-1,3,8,10(2H,9H)-tetrone (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3,4,9,10-Perylenetetracarboxylic 3,4:9,10-diimide (6CI, 7CI, 8CI)
OTHER NAMES:
CN 3,4,9,10-Perylenetetracarboxylic acid diimide
CN **3,4,9,10-Perylenetetracarboxylic diimide**
CN C.I. 71129
CN C.I. Pigment Brown 26
CN C.I. Pigment Violet 29
CN Euvinyl Maroon 478
CN NSC 16842
CN Paliogen Red Violet FM
CN Perrindo Violet V 4050
CN Perylimid
CN Pigment Violet 29
CN PTCDI
CN PV-Fast Bordeaux B
FS 3D CONCORD
DR 12236-71-4
MF C24 H10 N2 O4
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, SPECINFO, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

189 REFERENCES IN FILE CA (1962 TO DATE)
31 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
189 REFERENCES IN FILE CAPLUS (1962 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:106041

REFERENCE 2: 137:85715

REFERENCE 3: 137:79677

REFERENCE 4: 137:79671

REFERENCE 5: 137:79331

REFERENCE 6: 137:48617

REFERENCE 7: 137:48616

REFERENCE 8: 137:39571

REFERENCE 9: 137:17455

REFERENCE 10: 136:404263

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:42:49 ON 01 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

strictly prohibited.

FILE COVERS 1907 - 1 Oct 2002 VOL 137 ISS 14
FILE LAST UPDATED: 30 Sep 2002 (20020930/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d bib abs hitrn tot l102

L102 ANSWER 1 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:738893 HCAPLUS
DN 135:293717
TI Inhibitor of alkaline phosphatase for reduction of **hair** growth
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**
PA USA
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6299865	B1	20011009	US 2000-561657	20000502

AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of alk. phosphatase other than cromoglycate or a salt thereof. A topical compn. contained tetramisole 10% in a vehicle comprising water 68, ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, and propylene carbonate 2%. The compn. reduced **hair** growth in hamster by 62%.
RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 2 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:366720 HCAPLUS
DN 134:371790
TI Reduction of **hair** growth with ceramide analogs
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**
PA USA
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6235737	B1	20010522	US 2000-490486	20000125
WO 2001054654	A2	20010802	WO 2001-US2173	20010123
WO 2001054654	A3	20020221		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-490486 A1 20000125
AB Mammalian **hair** growth is reduced by applying to the skin a compn. that increases cellular ceramide levels. Compns. were prepd. contg. derivs. such as 1-phenyl-2-decanoylamino-3-morpholino-1-propanol or N-hexanoylsphingosine in vehicles and the compns. were tested for their effect on **hair** growth.

L102 ANSWER 3 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:608546 HCAPLUS
DN 133:198419
TI Reduction of **hair** growth by tyrosine kinase inhibitors
IN Henry, James P.; **Ahluwalia, Gurpreet S.**
PA The Gillette Company, USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000050002	A1	20000831	WO 2000-US4198	20000218
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6121269	A	20000919	US 1999-255063	19990222
BR 2000008239	A	20011106	BR 2000-8239	20000218
EP 1156775	A1	20011128	EP 2000-914636	20000218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1999-255063 A1 19990222
WO 2000-US4198 W 20000218
AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of protein-tyrosine kinase. A method is described for applying to the skin a compn. including an inhibitor of protein-tyrosine kinases in an amt. effective to reduce **hair** growth. The unwanted **hair** growth which is reduced may be normal **hair** growth, or **hair** growth that results from an abnormal or diseased condition. The preferred compn. includes at least one inhibitor of protein-tyrosine kinase in a cosmetically and/or dermatol. acceptable vehicle. The compn. may be a solid, semi-solid, or liq. The compn. may be, for example, a cosmetic and dermatol. product in the form of an, for example, ointment, lotion, foam, cream, gel, or hydroalcoholic soln. The compn. may also be in the form of a shaving prepn. or an aftershave. Human **hair** follicle growth assays showed that tyrphostin A48, erbstatin, lavendustin A, Me caffeate, and tyrphostin AG1478 showed the inhibition rate of 40-100 %.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 4 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:78846 HCAPLUS
DN 132:112773
TI Reduction of **hair** growth by inhibitors of alkaline phosphatase
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**
PA Gillette Co., USA
SO U.S., 5 pp.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6020006	A	20000201	US 1998-179267	19981027
WO 2000024368	A1	20000504	WO 1999-US23835	19991014

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9964289	A1	20000515	AU 1999-64289	19991014
BR 9914925	A	20010710	BR 1999-14925	19991014
EP 1124531	A1	20010822	EP 1999-951968	19991014

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI US 1998-179267	A1	19981027
WO 1999-US23835	W	19991014

AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of alk. phosphatase in a cosmetically and/or dermatol. acceptable vehicle. A compn. was prepd. contg. 10% tetramisole or 1% Na orthovanadate in a vehicle comprising water 68%, ethanol 16%, propylene glycol 5%, dipropylene glycol 5%, benzyl alc. 4%, and propylene carbonate 2%. Human **hair** follicle growth rate, quantified by **hair** follicle length, was inhibited in a dose dependent manner by these agents. Tetramisole caused a 42.+-.5% inhibition of **hair** growth at a 0.5 mM dose, and Na orthovanadate caused 58.+-.8% redn. in growth rate at a 0.1 mM concn.

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 5 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:635464 HCAPLUS
DN 131:252593
TI Reduction of **hair** growth using inhibitors of matrix metalloproteinases
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**; Shander, Douglas
PA USA
SO U.S., 5 pp., Cont.-in-part of U.S. Ser. No. 764,980, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5962466	A	19991005	US 1998-14187	19980127
ZA 9711121	A	19980623	ZA 1997-11121	19971210
WO 9962465	A1	19991209	WO 1998-US11083	19980601

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9877104	A1	19991220	AU 1998-77104	19980601

BR 9815884 A 20010220 BR 1998-15884 19980601
EP 1083863 A1 20010321 EP 1998-925074 19980601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
PRAI US 1996-764980 B2 19961213
WO 1998-US11083 A 19980601
AB Mammalian **hair** growth is reduced by inhibiting the activity of a matrix metalloproteinase in the skin.
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 6 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:487201 HCAPLUS
DN 131:120600
TI Reduction of **hair** growth with inhibitors of deoxyhypusine synthase and hydroxylase
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**; Shander, Douglas
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9937277	A1	19990729	WO 1998-US15649	19980727
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6060471	A	20000509	US 1998-10227	19980121
CA 2316826	AA	19990729	CA 1998-2316826	19980727
AU 9885982	A1	19990809	AU 1998-85982	19980727
BR 9814249	A	20001003	BR 1998-14249	19980727
EP 1049444	A1	20001108	EP 1998-937216	19980727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
ZA 9806822	A	19990202	ZA 1998-6822	19980730
PRAI US 1998-10227	A	19980121		
WO 1998-US15649	W	19980727		

AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of hypusine biosynthetic pathway. Golden Syrian hamster assay showed that 1,8-diaminooctane (deoxyhypusine synthase inhibitor) reduced the **hair** mass in a dose-dependent manner.
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 7 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:468558 HCAPLUS
DN 131:111451
TI Compounds that induce or activate androgen conjugation for modulation of **hair** growth
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**
PA The Gillette Company, USA
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9936067	A1	19990722	WO 1999-US1093	19990119
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 5958946	A	19990928	US 1998-9213	19980120
	CA 2320160	AA	19990722	CA 1999-2320160	19990119
	AU 9923266	A1	19990802	AU 1999-23266	19990119
	EP 1047420	A1	20001102	EP 1999-903183	19990119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9907090	A	20010904	BR 1999-7090	19990119
PRAI	US 1998-9213	A	19980120		
	WO 1999-US1093	W	19990119		

AB Mammalian **hair** growth may be modulated by applying to the skin a compd. that induces or activates the conjugation of an androgen.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 8 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:231491 HCAPLUS
DN 130:271878
TI Aminoacyl-tRNA synthetase inhibitors for reduction of **hair** growth
IN Handelman, Joseph H.; Henry, James P.; **Ahluwalia, Gurpreet S.**
PA USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915136	A1	19990401	WO 1998-US19521	19980918
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 5939458	A	19990817	US 1997-935181	19970922
	CA 2304807	AA	19990401	CA 1998-2304807	19980918
	AU 9893197	A1	19990412	AU 1998-93197	19980918
	EP 1017358	A1	20000712	EP 1998-946113	19980918
	R: DE, ES, FR, GB, IT				
	BR 9812369	A	20000919	BR 1998-12369	19980918
	ZA 9808641	A	19990323	ZA 1998-8641	19980921
PRAI	US 1997-935181	A	19970922		
	WO 1998-US19521	W	19980918		

AB Mammalian **hair** growth is reduced by applying an inhibitor of aminoacyl-tRNA synthetase to the skin. E.g., S-trityl-L-cysteine, formulated in a vehicle contg. 90% water, 6% dipropylene glycol, and 4% ethanol, at doses of 7.5, 5, and 1% inhibited the **hair** growth by 80, 56, and 35%, resp.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 9 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:774246 HCAPLUS
DN 130:29033
TI Reduction of **hair** growth
IN Henry, James P.; **Ahluwalia, Gurpreet S.**; Shander, Douglas
PA USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5840752	A	19981124	US 1996-754556	19961121
	CA 2311756	AA	19990617	CA 1997-2311756	19971205
	WO 9929288	A1	19990617	WO 1997-US22944	19971205
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9853817	A1	19990628	AU 1998-53817	19971205
	EP 1033962	A1	20000913	EP 1997-950948	19971205
	EP 1033962	B1	20020417		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9714903	A	20001010	BR 1997-14903	19971205
	AT 216215	E	20020515	AT 1997-950948	19971205
PRAI	US 1996-754556	A1	19961121		
	WO 1997-US22944	A	19971205		

AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of a cholesterol synthetic pathway enzyme.
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 10 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:484914 HCAPLUS
DN 129:140464
TI Reduction of **hair** growth by an inhibitor of a DNA topoisomerase
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**
PA Handelman, Joseph, H., USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829086	A1	19980709	WO 1997-US24268	19971223
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6037326	A	20000314	US 1996-777803	19961231
	ZA 9711328	A	19980623	ZA 1997-11328	19971217
	AU 9857302	A1	19980731	AU 1998-57302	19971223
	EP 957891	A1	19991124	EP 1997-953585	19971223

R: DE, ES, FR, GB, IT
PRAI US 1996-777803 A1 19961231
WO 1997-US24268 W 19971223
AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of a DNA topoisomerase. Application of a soln. of 10% nalidixic acid in 70% ethanol and 30% propylene glycol inhibited **hair** growth in hamster by 63%.

L102 ANSWER 11 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:402282 HCAPLUS
DN 129:71946
TI Reduction of **hair** growth
IN **Styczynski, Peter; Ahluwalia, Gurpreet S.**; Shander, Douglas
PA Handelman, Joseph, H., USA; Styczynski, Peter; Ahluwalia, Gurpreet S.; Shander, Douglas
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9825580	A1	19980618	WO 1997-US22587	19971212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9711121	A	19980623	ZA 1997-11121	19971210
AU 9855209	A1	19980703	AU 1998-55209	19971212
WO 9962465	A1	19991209	WO 1998-US11083	19980601
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9877104	A1	19991220	AU 1998-77104	19980601
BR 9815884	A	20010220	BR 1998-15884	19980601
EP 1083863	A1	20010321	EP 1998-925074	19980601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				

PRAI US 1996-764980 A1 19961213
WO 1997-US22587 W 19971212
WO 1998-US11083 A 19980601
AB Mammalian **hair** growth is reduced by inhibiting the activity of a matrix metalloproteinase (MMP) in the skin. For example, bromo cAMP was dissolved in a vehicle contg. water 68, ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, and propylene carbonate 2 % to obtain a 10 % concn. When the compn. was tested by the Golden Syrian hamster assay, it provided .apprx.80 % redn. in **hair** growth.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L102 ANSWER 12 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:87591 HCAPLUS
DN 128:171946
TI Reduction of **hair** growth by inhibiting the formation of

glycoproteins
IN Henry, James P.; **Ahluwalia, Gurpreet S.**; Kaszynski, Edwin; Shander, Douglas
PA Handelman, Joseph, H., USA; Henry, James P.; Ahluwalia, Gurpreet S.; Kaszynski, Edwin; Shander, Douglas
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9803149	A1	19980129	WO 1997-US11990	19970716
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5908867	A	19990601	US 1996-684287	19960718
AU 9735995	A1	19980210	AU 1997-35995	19970716
EP 938286	A1	19990901	EP 1997-932567	19970716
R: DE, ES, FR, GB, IT				
ZA 9711008	A	19980615	ZA 1997-11008	19971208
PRAI US 1996-684287	A1	19960718		
WO 1997-US11990	W	19970716		

AB A method of reducing **hair** growth in a mammal includes applying, to an area of skin from which reduced **hair** growth is desired, a dermatol. acceptable compn. contg. a compd. that inhibits the formation of glycoproteins, proteoglycans, or glycosaminoglycans in an amt. effective to cause a redn. in **hair** growth. D-Mannose was mixed at a concn. of 30 % in a vehicle contg. water 68, ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, and propylene carbonate 2 % and when tested in the Golden Syrian hamster assay, **hair** growth inhibition by 77 % was obsd.

L102 ANSWER 13 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:461636 HCAPLUS
DN 127:85813
TI Reduction of **hair** growth with suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA
IN Henry, James; **Ahluwalia, Gurpreet**; Shander, Douglas
PA Handelman, Joseph, H., USA; Henry, James; Ahluwalia, Gurpreet; Shander, Douglas
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9719673	A2	19970605	WO 1996-US19102	19961125
WO 9719673	A3	19971002		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

	US 5652273	A	19970729	US 1995-565728	19951130
	ZA 9609781	A	19970610	ZA 1996-9781	19961121
	CA 2237780	AA	19970605	CA 1996-2237780	19961125
	AU 9710865	A1	19970619	AU 1997-10865	19961125
	AU 728886	B2	20010118		
	EP 863741	A2	19980916	EP 1996-940921	19961125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9611756	A	19990406	BR 1996-11756	19961125
	JP 2000501098	T2	20000202	JP 1997-520706	19961125
	US 5824665	A	19981020	US 1997-842054	19970423
	US 6218435	B1	20010417	US 1998-118946	19980717
PRAI	US 1995-565728	A1	19951130		
	WO 1996-US19102	W	19961125		
	US 1997-842054	A3	19970423		

AB A method of reducing **hair** growth in a mammal includes applying, to an area of skin from which reduced **hair** growth is desired, dermatol. acceptable compn. contg. a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA. A 10% soln. of N-.alpha.-(p-tosyl)-L-lysine chloromethyl ketone in a vehicle comprising water 68, ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, and propylene carbonate 2% inhibited **hair** growth in hamster by 81%.

L102 ANSWER 14 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:443396 HCAPLUS
DN 127:70606
TI Reduction of **hair** growth by arginase inhibitors
IN Shander, Douglas; Funkhouser, Margaret; Henry, James; **Ahluwalia, Gurpreet**
PA Handelman, Joseph, H., USA; Shander, Douglas; Funkhouser, Margaret; Henry, James; Ahluwalia, Gurpreet
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9719672	A1	19970605	WO 1996-US18788	19961121
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5728736	A	19980317	US 1995-564491	19951129
	CA 2237979	AA	19970605	CA 1996-2237979	19961121
	ZA 9609773	A	19970617	ZA 1996-9773	19961121
	AU 9710237	A1	19970619	AU 1997-10237	19961121
	AU 723723	B2	20000907		
	EP 863740	A1	19980916	EP 1996-940597	19961121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9611822	A	19990713	BR 1996-11822	19961121
	JP 2000501096	T2	20000202	JP 1997-520571	19961121
PRAI	US 1995-564491	A1	19951129		
	WO 1996-US18788	W	19961121		

AB Mammalian **hair** growth is reduced by applying to the skin a dermatol. acceptable compn. including an inhibitor of arginase. Application of daily soln. of 10% N-G-hydroxy-L-arginine in a carrier comprising ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, propylene carbonate 2, and water 68% to hamster skin for 13 day

reduced **hair** growth by 66%.

L102 ANSWER 15 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:660913 HCAPLUS
DN 125:293042
TI Use of angiogenesis suppressors for inhibiting **hair** growth
IN **Ahluwalia, Gurpreet S.; Styczynski, Peter;** Shander, Douglas
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626712	A2	19960906	WO 1996-US2790	19960227
	WO 9626712	A3	19961121		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	CA 2213404	AA	19960906	CA 1996-2213404	19960227
	AU 9653009	A1	19960918	AU 1996-53009	19960227
	AU 719106	B2	20000504		
	EP 812185	A2	19971217	EP 1996-909552	19960227
	EP 812185	B1	20020703		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	BR 9607060	A	19981215	BR 1996-7060	19960227
	JP 11501035	T2	19990126	JP 1996-526415	19960227
	AT 219928	E	20020715	AT 1996-909552	19960227
	ZA 9601600	A	19960905	ZA 1996-1600	19960228
	US 6093748	A	20000725	US 1997-963227	19971103
PRAI	US 1995-396446	A	19950228		
	WO 1996-US2790	W	19960227		

AB A method of inhibiting **hair** growth in a mammal includes applying, to an area of skin from which reduced **hair** growth is desired, a dermatol. acceptable compn. contg. a non-steroidal suppressor of angiogenesis. The effective compds. include sulfotransferase inhibitors, heparin binding antagonists, Cu chelators, histidine decarboxylase inhibitors, mast cell degranulation inhibitors, histamine receptor antagonists, ACE inhibitors, angiotensin II receptor antagonists, prostaglandin synthetase inhibitors, NK1 receptor antagonists, PAF receptor antagonists, and cytochrome P 450 reductase inhibitors. A topical prepn. contg. 10 % bathocuproine, was applied to male intact Golden Syrian hamsters; **hair** growth was inhibited by 81 %.

L102 ANSWER 16 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:656422 HCAPLUS
DN 125:284345
TI **Hair** growth inhibitors comprising a catechin compound
IN **Ahluwalia, Gurpreet S.**
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626705	A1	19960906	WO 1996-US2791	19960227

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML

	US 5674477	A	19971007	US 1995-396426	19950228
	CA 2213411	AA	19960906	CA 1996-2213411	19960227
	AU 9651781	A1	19960918	AU 1996-51781	19960227
	AU 720440	B2	20000601		
	EP 814754	A1	19980107	EP 1996-908589	19960227
	EP 814754	B1	20011205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	BR 9607061	A	19981215	BR 1996-7061	19960227
	JP 11501036	T2	19990126	JP 1996-526416	19960227
	AT 209890	E	20011215	AT 1996-908589	19960227
	ES 2164877	T3	20020301	ES 1996-908589	19960227
	ZA 9601599	A	19960905	ZA 1996-1599	19960228
	US 5776442	A	19980707	US 1997-893319	19970716
PRAI	US 1995-396426	A	19950228		
	WO 1996-US2791	W	19960227		

AB Mammalian **hair** growth is reduced by applying to the skin a dermatol. acceptable compn. including a catechin compd. A mixt. of catechins extd. from tea leaves contained epigallocatechin 4.6, epigallocatechin gallate 69.6, epicatechin 6.7, and epicatechin gallate 19.1%. Daily application of the mixt. in a vehicle comprising water 68, ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, and propylene carbonate 2% to hamster skin, decreased the **hair** growth by 91% after 13 application.

L102 ANSWER 17 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:354097 HCAPLUS
DN 125:18662
TI Inhibition of **hair** growth with protein kinase C inhibitors
IN **Ahluwalia, Gurpreet S.**; Shander, Douglas; **Styczynski, Peter**
PA Handelman, Joseph, H., USA
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9609806	A2	19960404	WO 1995-US12134	19950921
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5554608	A	19960910	US 1994-314327	19940928
	CA 2200851	AA	19960404	CA 1995-2200851	19950921
	AU 9537230	A1	19960419	AU 1995-37230	19950921
	AU 700683	B2	19990114		
	EP 783292	A1	19970716	EP 1995-935068	19950921
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 2001525789	T2	20011211	JP 1996-511904	19950921
	ZA 9508145	A	19960425	ZA 1995-8145	19950927
PRAI	US 1994-314327	A1	19940928		
	WO 1995-US12134	W	19950921		

AB Mammalian **hair** growth is reduced by applying to the skin a

compn. including an inhibitor of protein kinase C (PKC). The inhibitor interacts with the ATP-binding site, Ca-binding site, or phospholipid-interacting site in PKC. The compn. provides a redn. in **hair** growth of .gtoreq.30% when tested in the Golden Syrian hamster assay. A no. of PKC inhibitors were tested in the Golden Syrian hamster assay; e.g. verapamil, thioridazine, curcumin, and trifluoperazine inhibited **hair** growth by 56-69%.

L102 ANSWER 18 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:926476 HCAPLUS
DN 123:321734
TI Cysteine synthetic pathway enzyme inhibitors to retard unwanted **hair** growth
IN **Ahluwalia, Gurpreet S.**; Shander, Douglas
PA Handleman, Joseph H., USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9524885	A1	19950921	WO 1995-US2902	19950310
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5455234	A	19951003	US 1994-213954	19940316
	CA 2184173	AA	19950921	CA 1995-2184173	19950310
	AU 9519844	A1	19951003	AU 1995-19844	19950310
	AU 696304	B2	19980903		
	EP 750489	A1	19970102	EP 1995-912803	19950310
	EP 750489	B1	19981118		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09510448	T2	19971021	JP 1995-524077	19950310
	AT 173392	E	19981215	AT 1995-912803	19950310
	ES 2123968	T3	19990116	ES 1995-912803	19950310
	ZA 9502098	A	19951211	ZA 1995-2098	19950314
PRAI	US 1994-213954		19940316		
	WO 1995-US2902		19950310		

AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of a cysteine synthetic pathway enzyme, such as methionine S-adenosyltransferase, L-homocysteine S-methyltransferase, S-adenosylhomocysteine hydrolase, cystathionine synthase, and cystathionase. For example, a topical compn. comprised 5% 3-deazaneplanocin in a vehicle contg. ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, propylene carbonate 2, and pure water 68%. The compn. inhibited **hair** mass by 86.65% in male Golden Syrian hamster model.

L102 ANSWER 19 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:926475 HCAPLUS
DN 123:321733
TI Nitric oxide synthetase inhibitors for inhibition of unwanted **hair** growth
IN **Ahluwalia, Gurpreet S.**; Shander, Douglas; Henry, James P.
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9524884	A1	19950921	WO 1995-US2898	19950310
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5468476	A	19951121	US 1994-213931	19940316
	CA 2184171	AA	19950921	CA 1995-2184171	19950310
	AU 9519843	A1	19951003	AU 1995-19843	19950310
	AU 681776	B2	19970904		
	EP 754023	A1	19970122	EP 1995-912801	19950310
	EP 754023	B1	19990526		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09510447	T2	19971021	JP 1995-524076	19950310
	AT 180404	E	19990615	AT 1995-912801	19950310
	ES 2131822	T3	19990801	ES 1995-912801	19950310
	ZA 9502095	A	19951211	ZA 1995-2095	19950314
PRAI	US 1994-213931		19940316		
	WO 1995-US2898		19950310		

AB Mammalian **hair** growth is reduced by applying to the skin an inhibitor of nitric oxide synthetase. A topical compn. contains 1-30 % of the inhibitor, such as NG-methyl-L-arginine to provide a redn. in **hair** growth by .gtoreq.30%, when tested in the Golden Syrian hamster assay.

L102 ANSWER 20 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:872304 HCAPLUS
DN 123:265813
TI Method of reducing the rate of **hair** growth with asparagine synthetase inhibitors
IN **Ahluwalia, Gurpreet S.**
PA USA
SO U.S., 3 pp. Cont.-in-part of U.S. Ser. No. 788,168, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5444090	A	19950822	US 1994-212584	19940311
	CA 2122002	C	19971216	CA 1992-2122002	19921104
PRAI	US 1991-788168	B2	19911105		

AB The rate and character of mammalian **hair** growth is altered by the topical application to the skin of a compn. contg. an org. inhibitor of asparagine synthetase. The inhibitors include guanidinosuccinic acid, oxaloacetic acid, cysteinesulfinic acid, di-Et aminomalonate, and ethacrynic acid. A topical compn. is particularly effective to reduce the androgen-stimulated **hair** growth. The compn. provides a redn. in **hair** growth by .gtoreq.23.3% when tested in the Golden Syrian hamster assay.

L102 ANSWER 21 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:324868 HCAPLUS
DN 122:89132
TI Inhibitors of 5-lipoxygenase for prevention of **hair** growth
IN **Ahluwalia, Gurpreet S.**; Shander, Douglas
PA Handelman, Joseph, H., USA

SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9427563	A1	19941208	WO 1994-US5361	19940516
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6239170	B1	20010529	US 1993-68256	19930528
CA 2163534	AA	19941208	CA 1994-2163534	19940516
CA 2163534	C	19981215		
AU 9468331	A1	19941220	AU 1994-68331	19940516
AU 680257	B2	19970724		
EP 700282	A1	19960313	EP 1994-916767	19940516
EP 700282	B1	19981007		
R: DE, ES, FR, GB, IT				
JP 08510735	T2	19961112	JP 1994-500714	19940516
ES 2122283	T3	19981216	ES 1994-916767	19940516
ZA 9403612	A	19950125	ZA 1994-3612	19940524
US 2001048932	A1	20011206	US 2001-765106	20010118
US 6414017	B2	20020702		
PRAI US 1993-68256	A	19930528		
US 1993-68257	A2	19930528		
WO 1994-US5361	W	19940516		
US 2000-584281	B1	20000531		

AB Mammalian **hair** growth is inhibited by applying to the skin a compn. including an inhibitor of 5-lipoxygenase. The enzyme inhibitor is selected from quercetin, DL-.alpha.-tocopherol, apigenin, Pr gallate, nordihydroguaiaretic acid, and caffeic acid. The effective amts. of the compd. range from 100 to 3000 .mu.g per cm2 of skin and the compn. is applied once or twice for at least 3 mo to achieve a perceived redn. in **hair** growth.

L102 ANSWER 22 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:320081 HCAPLUS
DN 122:89083
TI Inhibition of **hair** growth with cyclooxygenase inhibitors
IN **Ahluwalia, Gurpreet S.**; Shander, Douglas
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9427586	A1	19941208	WO 1994-US5360	19940516
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6248751	B1	20010619	US 1993-68257	19930528
CA 2163535	AA	19941208	CA 1994-2163535	19940516
AU 9470181	A1	19941220	AU 1994-70181	19940516
AU 677346	B2	19970417		
EP 700288	A1	19960313	EP 1994-919136	19940516
EP 700288	B1	20010718		

R: DE, ES, FR, GB, IT

	JP 08510734	T2	19961112	JP 1994-500713	19940516
	ES 2159560	T3	20011016	ES 1994-919136	19940516
	ZA 9403611	A	19950125	ZA 1994-3611	19940524
	US 2001048932	A1	20011206	US 2001-765106	20010118
	US 6414017	B2	20020702		
PRAI	US 1993-68257	A	19930528		
	US 1993-68256	A2	19930528		
	WO 1994-US5360	W	19940516		
	US 2000-584281	B1	20000531		

AB Mammalian **hair** growth is reduced by applying to the skin a compn. including an inhibitor of cyclooxygenase. A formulation contg. 20% indomethacin reduced **hair** growth in hamster after 13 application (1 application/day for 5 days a wk) by 78.43%.

L102 ANSWER 23 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1994:686338 HCAPLUS
DN 121:286338
TI Topical composition for inhibiting **hair** growth containing .alpha.-(difluoromethyl)ornithine
IN Boxall, Brian Alfred; Amery, Geoffrey Wilfred; **Ahluwalia, Gurpreet S.**
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9421216	A1	19940929	WO 1993-US2684	19930319
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9339310	A1	19941011	AU 1993-39310	19930319
	CA 2158041	AA	19940929	CA 1993-2158041	19930527
	WO 9421217	A1	19940929	WO 1993-US5068	19930527
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9345243	A1	19941011	AU 1993-45243	19930527
	AU 684251	B2	19971211		
	EP 689416	A1	19960103	EP 1993-915148	19930527
	EP 689416	B1	19981104		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	JP 08507785	T2	19960820	JP 1993-520992	19930527
	PL 174475	B1	19980831	PL 1993-310679	19930527
	AT 172871	E	19981115	AT 1993-915148	19930527
	ES 2125339	T3	19990301	ES 1993-915148	19930527
	RU 2139705	C1	19991020	RU 1995-122131	19930527
	IL 109536	A1	19980310	IL 1994-109536	19940503
	CN 1097982	A	19950201	CN 1994-106181	19940521
	ZA 9403561	A	19950126	ZA 1994-3561	19940523
	NO 9503580	A	19950911	NO 1995-3580	19950911
	US 5648394	A	19970715	US 1995-513980	19950914
PRAI	WO 1993-US2684	W	19930319		
	WO 1993-US5068	W	19930527		

AB A topical compn. for inhibiting mammalian **hair** growth, particularly human beard **hair** growth (including hirsutism),

comprises a water-sol., **hair**-growth-inhibiting agent, .alpha.-(difluoromethyl)ornithine (I) dispersed in an oil-in-water emulsion in the form of a lotion or cream. A topical emulsion contained water 80.84, glyceryl stearate 4.24, PEG stearate 4.09, cetearyl alc. 3.05, ceteareth-20 2.50, mineral oil 2.22, stearyl alc. 1.67, dimethicone 0.56, I 10%, and NaOH q.s. pH=3.5. The **hair** growth inhibition of the above emulsion in hamster was 87.6% as compared to control contg. no I.

L102 ANSWER 24 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1994:541665 HCAPLUS
DN 121:141665
TI Reduction of **hair** growth employing sulfhydryl reactive compounds
IN Shander, Douglas; **Ahluwalia, Gurpreet S.**; Mark-Del Grosso, Diana
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9414428	A1	19940707	WO 1993-US12266	19931216
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5411991	A	19950502	US 1992-995037	19921222
	CA 2152350	AA	19940707	CA 1993-2152350	19931216
	CA 2152350	C	19980505		
	AU 9459531	A1	19940719	AU 1994-59531	19931216
	AU 687778	B2	19980305		
	EP 675712	A1	19951011	EP 1994-905412	19931216
	EP 675712	B1	20010919		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	AT 205710	E	20011015	AT 1994-905412	19931216
	ES 2163429	T3	20020201	ES 1994-905412	19931216
	ZA 9309635	A	19940815	ZA 1993-9635	19931222
PRAI	US 1992-995037	A	19921222		
	WO 1993-US12266	W	19931216		

AB A method of reducing the rate of mammalian **hair** growth includes topically applying a compn. contg. a SH reactive compd. to the skin. The SH reactive compds., such as cysteamine, D-penicillamine, captopril, and thiosalicylic acid, penetrate into **hair** follicles in the skin and reacts with free cysteine in the **hair** follicle cells to form cysteine-mixed disulfides.

L102 ANSWER 25 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1994:491309 HCAPLUS
DN 121:91309
TI Pantothenic acid and pantothenyl alcohol for inhibition of **hair** growth
IN **Ahluwalia, Gurpreet S.**; Shander, Douglas
PA USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9410967	A1	19940526	WO 1993-US10920	19931110

W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU; LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US	5364885	A	19941115	US 1992-976446	19921113
CA	2149316	AA	19940526	CA 1993-2149316	19931110
CA	2149316	C	19980922		
AU	9455529	A1	19940608	AU 1994-55529	19931110
AU	690086	B2	19980423		
EP	667766	A1	19950823	EP 1994-900614	19931110
EP	667766	B1	19970813		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE

JP	08503220	T2	19960409	JP 1993-512359	19931110
AT	156698	E	19970815	AT 1994-900614	19931110
ES	2107789	T3	19971201	ES 1994-900614	19931110
PRAI US	1992-976446		19921113		
WO	1993-US10920		19931110		

AB Mammalian **hair** growth is cosmetically reduced by applying to the skin a compn. including pantothenic acid or pantothenyl alc. (1-30%).

L102 ANSWER 26 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1993:434298 HCAPLUS
DN 119:34298
TI Alteration of rate and character of **hair** growth
IN Handelman, Joseph H.; **Ahluwalia, Gurpreet S.**
PA USA
SO PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 9308687	A1	19930513	WO 1992-US9438	19921104

W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG

AU	9230627	A1	19930607	AU 1992-30627	19921104
AU	670554	B2	19960725		
EP	612211	A1	19940831	EP 1992-924244	19921104
EP	612211	B1	20020605		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, SE

JP	07504646	T2	19950525	JP 1992-508679	19921104
CA	2122002	C	19971216	CA 1992-2122002	19921104
AT	218273	E	20020615	AT 1992-924244	19921104
PRAI US	1991-788168	A1	19911105		
WO	1992-US9438	A	19921104		

AB The rate and character of mammalian **hair** growth are altered by the topical application to the skin of a compn. contg. an org. inhibitor of the enzyme L-asparagine synthetase. A topical compn. for reducing the rate and altering the character of mammalian **hair** growth comprises a nontoxic dermatol. acceptable vehicle and from 0.1 to 30 % based on the total wt. of the compn. of an org. inhibitor of L-asparagine synthetase, such as guanidinosuccinic acid.

L102 ANSWER 27 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1992:221336 HCAPLUS
DN 116:221336
TI Enzymic alteration of **hair** growth
IN Handelman, Joseph H.; Shander, Douglas; Harrington, Eugene F.; **Ahluwalia, Gurpreet S.**

PA USA
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9203140	A1	19920305	WO 1991-US5721	19910812
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 2088909	AA	19920215	CA 1991-2088909	19910812
	AU 9187232	A1	19920317	AU 1991-87232	19910812
	AU 657710	B2	19950323		
	EP 543949	A1	19930602	EP 1991-918121	19910812
	EP 543949	B1	19971022		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 06500335	T2	19940113	JP 1991-516613	19910812
	JP 3299961	B2	20020708		
	AT 159428	E	19971115	AT 1991-918121	19910812
	ES 2109949	T3	19980201	ES 1991-918121	19910812
	US 5132293	A	19920721	US 1991-784650	19911028
PRAI	US 1990-567018	A1	19900814		
	WO 1991-US5721	A	19910812		

AB Mammalian **hair** growth is inhibited by application to the skin of an inhibitor of S-adenosylmethionine decarboxylase (I), alone or combined with an inhibitor of ornithine decarboxylase (II). Such compns. are useful for treatment of e.g. female hirsutism. Thus, a compn. contg. water 68, EtOH 16, propylene glycol 5, dipropylene glycol 5, PhCH2OH 4, propylene carbonate 2, 5'-deoxy-5'-[N-methyl-N-[2-(aminooxy)ethyl]aminoadenosine (I inhibitor) 5, and 2-(difluoromethyl)ornithine (II inhibitor) 5 parts, applied at 10 .mu.L/day topically to the shaved flank organ of golden Syrian hamsters, inhibited **hair** growth by 70.9%.

L102 ANSWER 28 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1992:188094 HCAPLUS
DN 116:188094
TI Alteration of rate and character of **hair** growth by topical application of inhibitors of adenylosuccinate synthetase or aspartate transcarbamylase
IN **Ahluwalia, Gurpreet S.**
PA USA
SO U.S., 3 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5095007	A	19920310	US 1990-603999	19901024
	WO 9207569	A1	19920514	WO 1991-US7839	19911022
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	AU 9189289	A1	19920526	AU 1991-89289	19911022
	AU 662112	B2	19950824		
	EP 554363	A1	19930811	EP 1991-920173	19911022
	EP 554363	B1	19980624		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				

	JP 06502648	T2	19940324	JP 1992-501257	19911022
	AT 167625	E	19980715	AT 1991-920173	19911022
	ES 2117646	T3	19980816	ES 1991-920173	19911022
PRAI	US 1990-603999		19901024		
	WO 1991-US7839		19911022		

AB The rate and character of mammalian **hair** growth is altered by the topical application of inhibitors of adenylosuccinate synthetase or aspartate transcarbamylase. Topical treatment with a 10% soln. of L-alanosine, twice over a 24-h period, resulted in .apprx.49% inhibition of adenylosuccinate synthetase activity in hamster **hair** follicles.

L102 ANSWER 29 OF 29 HCAPLUS COPYRIGHT 2002 ACS
AN 1992:158565 HCAPLUS
DN 116:158565
TI Alteration of rate and character of **hair** growth with .gamma.-glutamyl transpeptidase inhibitor
IN **Ahluwalia, Gurpreet S.**; Shander, Douglas; Harrington, F. Eugene
PA Handelman, Joseph H., USA
SO PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9200069	A1	19920109	WO 1991-US4427	19910621
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	US 5096911	A	19920317	US 1990-542586	19900625
	CA 2085885	AA	19911226	CA 1991-2085885	19910621
	AU 9182094	A1	19920123	AU 1991-82094	19910621
	AU 663292	B2	19951005		
	JP 06502389	T2	19940317	JP 1991-511788	19910621
	EP 607124	A1	19940727	EP 1991-912670	19910621
	EP 607124	B1	19970813		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 156708	E	19970815	AT 1991-912670	19910621
	ES 2104710	T3	19971016	ES 1991-912670	19910621
PRAI	US 1990-542586		19900625		
	WO 1991-US4427		19910621		

AB Mammalian **hair** growth is inhibited with .gamma.-glutamyl transpeptidase inhibitor. The flank organs of male Golden Syrian hamsters were treated topically with 6.0% acivicin. **Hair** growth was inhibited by 81.0%. Anthglutin was prepd. and used to inhibit **hair** growth.

=> fil medline
FILE 'MEDLINE' ENTERED AT 15:52:59 ON 01 OCT 2002

FILE LAST UPDATED: 28 SEP 2002 (20020928/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> d all tot l136

L136 ANSWER 1 OF 8 MEDLINE
AN 2001281142 MEDLINE
DN 97702816 PubMed ID: 11364534
TI Hydroxyurea.
AU Bowers M
SO BETA, (1997 Mar) 9-11.
Journal code: 9113964. ISSN: 1058-708X.
CY United States
DT (NEWSPAPER ARTICLE)
LA English
FS AIDS
EM 199708
ED Entered STN: 20010529
Last Updated on STN: 20020222
Entered Medline: 19970813
AB Hydroxyurea, an inhibitor of ribonucleotide reductase in cells, is among the strategies being used to reduce HIV levels. Hydroxyurea disrupts DNA synthesis in rapidly dividing cells and reduces the number of deoxyribonucleotides available to make functional viral products. The combination of hydroxyurea and **ddI** have shown a positive synergistic effect in reducing HIV viral load. Side effects are influenced by dosage, and include **hair loss** and bone marrow suppression, making it an inappropriate therapy for people with anemia. Results from completed clinical studies have left unanswered questions on the most appropriate dose of hydroxyurea, who should take it, and when therapy should begin.
CT Check Tags: Human
Alopecia: CI, chemically induced
Anemia: CI, chemically induced
Bone Marrow: DE, drug effects
DNA Replication: DE, drug effects
Enzyme Inhibitors: AE, adverse effects
Enzyme Inhibitors: PD, pharmacology
*Enzyme Inhibitors: TU, therapeutic use
*HIV Infections: DT, drug therapy
HIV Infections: VI, virology
Hydroxyurea: AE, adverse effects
Hydroxyurea: PD, pharmacology
*Hydroxyurea: TU, therapeutic use
Ribonucleotide Reductases: AI, antagonists & inhibitors
Viral Load
RN 127-07-1 (Hydroxyurea)
CN 0 (Enzyme Inhibitors); EC 1.17.4 (Ribonucleotide Reductases)

L136 ANSWER 2 OF 8 MEDLINE
AN 2000385738 MEDLINE
DN 20307977 PubMed ID: 10846257
TI Cutaneous side effects induced by indinavir.
AU Calista D; Boschini A
CS Dermatology Unit "M. Bufalini" Hospital, 47023 Cesena, Italy.
SO EUROPEAN JOURNAL OF DERMATOLOGY, (2000 Jun) 10 (4) 292-6.
Journal code: 9206420. ISSN: 1167-1122.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 200008
ED Entered STN: 20000818
Last Updated on STN: 20000818
Entered Medline: 20000810
AB HIV-protease inhibitors demonstrated such high efficacy in short-term

studies that they have been approved by the FDA, even though possible toxicity still needs further investigation. In the period between January 1997 and August 1998, 101 patients, staying at San Patrignano Medical Centre (Italy), received an HIV protease inhibitor (indinavir) plus two nucleoside reverse transcriptase inhibitors (NRTI's) selected from the following: **AZT**, didanosine, zalcitabine, lamivudine or stavudine. Seventy-three patients were male, 28 female and their ages ranged from 25 to 60 years, with an average of 34. At the end of the study, 84 patients were suitable for evaluation, as the other 17 dropped out for various reasons. Forty-eight patients (57.1%) developed cheilitis, 34 (40.5%) experienced diffuse cutaneous dryness and pruritus, 10 (11.9%) developed asteatotic dermatitis on the trunk, arms and thighs and another 10 (11.9%) complained of scalp defluvium. A severe **alopecia** was observed in only 1 patient (1.2%), while 6 reported that their body hair had become fairer, thinner and shed considerably. Multiple pyogenic granulomas were observed in the toenails of 5 patients (5. 9%). Softening of the nail plate was noted in 5 subjects as well. A peripheral lipodystrophy syndrome was noted in 12 patients (14.3%). Among these, one patient only developed a "buffalo hump" and another had diffused lipomatosis. The temporal relationship between the taking of indinavir and the onset of such cutaneous effects was striking. This was confirmed by the regression of symptoms in those patients who later discontinued indinavir. The emerging side effects of protease inhibitors require a multidisciplinary team for adequate diagnosis and treatment. Cutaneous toxicity involving the patient's own body image has a peculiar influence on compliance to the treatment and the patient's quality of life.

CT Check Tags: Comparative Study; Female; Human; Male
Adult
Alopecia: CI, chemically induced
Alopecia: PA, pathology
Didanosine: AE, adverse effects
*Drug Eruptions: ET, etiology
Drug Eruptions: PA, pathology
Drug Therapy, Combination
HIV: GE, genetics
HIV Infections: DT, drug therapy
*HIV Protease Inhibitors: AE, adverse effects
*Indinavir: AE, adverse effects
Lamivudine: AE, adverse effects
Lipodystrophy: CI, chemically induced
Lipodystrophy: PA, pathology
Middle Age
Pruritus: CI, chemically induced
Pruritus: PA, pathology
Pyoderma Gangrenosum: CI, chemically induced
Pyoderma Gangrenosum: PA, pathology
RNA, Viral: AN, analysis
Retrospective Studies
Reverse Transcriptase Inhibitors: AE, adverse effects
Scalp Dermatoses: CI, chemically induced
Scalp Dermatoses: PA, pathology
*Skin: DE, drug effects
Skin: PA, pathology
Stavudine: AE, adverse effects
Zalcitabine: AE, adverse effects
Zidovudine: AE, adverse effects

RN 134678-17-4 (Lamivudine); 150378-17-9 (Indinavir); **30516-87-1 (Zidovudine); 3056-17-5 (Stavudine); 69655-05-6 (Didanosine)**; 7481-89-2 (Zalcitabine)

CN 0 (HIV Protease Inhibitors); 0 (RNA, Viral); 0 (Reverse Transcriptase Inhibitors)

L136 ANSWER 3 OF 8 MEDLINE

AN 1999189755 MEDLINE
DN 99189755 PubMed ID: 10089885
TI Longevity, stress response, and cancer in aging **telomerase** -deficient mice.
AU Rudolph K L; Chang S; Lee H W; Blasco M; Gottlieb G J; Greider C; DePinho R A
CS Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.
SO CELL, (1999 Mar 5) 96 (5) 701-12.
Journal code: 0413066. ISSN: 0092-8674.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199904
ED Entered STN: 19990504
Last Updated on STN: 19990504
Entered Medline: 19990422
AB Telomere maintenance is thought to play a role in signaling cellular senescence; however, a link with organismal aging processes has not been established. The **telomerase** null mouse provides an opportunity to understand the effects associated with critical telomere shortening at the organismal level. We studied a variety of physiological processes in an aging cohort of mTR-/- mice. Loss of telomere function did not elicit a full spectrum of classical pathophysiological symptoms of aging. However, age-dependent telomere shortening and accompanying genetic instability were associated with shortened life span as well as a reduced capacity to respond to stresses such as wound healing and hematopoietic ablation. In addition, we found an increased incidence of spontaneous malignancies. These findings demonstrate a critical role for telomere length in the overall fitness, reserve, and well being of the aging organism.
CT Check Tags: Animal; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Aging: GE, genetics
*Aging: PH, physiology
Alopecia: ET, etiology
Body Weight
Bone Marrow Diseases: CI, chemically induced
Bone Marrow Diseases: PP, physiopathology
Fluorouracil: TO, toxicity
Hair Color: GE, genetics
*Longevity: PH, physiology
Mice
Mice, Knockout
Neoplasms, Experimental: EN, enzymology
*Neoplasms, Experimental: ET, etiology
Neoplasms, Experimental: GE, genetics
Skin: IN, injuries
Skin: PA, pathology
Stress: EN, enzymology
*Stress: PP, physiopathology
***Telomerase: DF, deficiency**
Telomerase: GE, genetics
Telomerase: PH, physiology
Telomere: UL, ultrastructure
Wound Healing
RN 51-21-8 (Fluorouracil)
CN EC 2.7.7.- (**Telomerase**)

L136 ANSWER 4 OF 8 MEDLINE
AN 1999136041 MEDLINE
DN 99136041 PubMed ID: 9949294
TI Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.

AU Hietanen P; Teerenhovi L; Joensuu H
CS Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.. paivi.hietanen@huch.fi
SO ONCOLOGY, (1999) 56 (2) 103-9.
Journal code: 0135054. ISSN: 0030-2414.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199903
ED Entered STN: 19990326
Last Updated on STN: 19990326
Entered Medline: 19990318
AB Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF). The dose of cyclophosphamide was increased by 250 mg/m2 starting from the dose of 1,000 mg/m2. Mesna was given to prevent cystitis. The criteria for dose-limiting toxicity were grade IV granulocytopenia lasting for longer than 48 h, granulocytopenic infection or other grade IV toxicities. G-CSF and **ofloxacin** were used if grade IV granulocytopenia continued for longer than 48 h or if granulocytopenic infection occurred. At the dose level of 1,500 mg/m2 (500 mg/m2/week) 22 (92%) of the 24 patients had grade IV granulocytopenia during the 6 CMF cycles given, but only 3 (13%) had granulocytopenic fever. G-CSF was used in 28% of the cycles at this dose level. Other toxicities included complete **alopecia** (79%), nausea and vomiting. Sixteen (80%) of the premenopausal women became postmenopausal. At the dose level of 1,750 mg/m2 all 3 patients treated had to be hospitalized after the first cycle due to neutropenic infection (n = 2) or intractable vomiting even though prophylactic G-CSF was used. We conclude that intravenous CMF with a cyclophosphamide dose of 1,500 mg/m2 given at 3-week intervals with the selective use of prophylactic G-CSF is feasible as adjuvant treatment for patients with breast cancer.
CT Check Tags: Female; Human; Support, Non-U.S. Gov't
Adult
Aged
*Agranulocytosis: CI, chemically induced
Agranulocytosis: PC, prevention & control
Alopecia: CI, chemically induced
Ambulatory Care
*Antineoplastic Combined Chemotherapy Protocols: AD, administration & dosage
*Antineoplastic Combined Chemotherapy Protocols: AE, adverse effects
Bladder: DE, drug effects
*Breast Neoplasms: DT, drug therapy
Conjunctivitis: CI, chemically induced
Cyclophosphamide: AD, administration & dosage
Cyclophosphamide: AE, adverse effects
Drug Administration Schedule
Fluorouracil: AD, administration & dosage
Fluorouracil: AE, adverse effects
Gastrointestinal Diseases: CI, chemically induced
Granulocyte Colony-Stimulating Factor: TU, therapeutic use
Methotrexate: AD, administration & dosage
Methotrexate: AE, adverse effects
Middle Age
Neutropenia: CI, chemically induced
Treatment Outcome
RN 143011-72-7 (Granulocyte Colony-Stimulating Factor); 50-18-0 (Cyclophosphamide); 51-21-8 (Fluorouracil); 59-05-2 (Methotrexate)

CN 0 (Antineoplastic Combined Chemotherapy Protocols); 0 (CMF regimen)

L136 ANSWER 5 OF 8 MEDLINE
AN 1998409228 MEDLINE
DN 98409228 PubMed ID: 9738848
TI Comparative grepafloxacin phototoxicity in mouse skin.
AU Owen K
CS GlaxoWellcome Research and Development, Ware, Hertfordshire, UK.
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (1998 Aug) 42 (2) 261-4.
Journal code: 7513617. ISSN: 0305-7453.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199811
ED Entered STN: 19990106
Last Updated on STN: 19990106
Entered Medline: 19981117
AB This study was performed in order to compare the phototoxic potential of grepafloxacin (a new fluoroquinolone for the treatment of respiratory tract infections) with that of a number of marketed fluoroquinolones. Groups of Balb/c mice received either control material or grepafloxacin, lomefloxacin, sparfloxacin, **ofloxacin**, ciprofloxacin or enoxacin at an oral dose of 200 mg/kg before being exposed to 20 J/cm2 longwave ultraviolet irradiation for 110-115 min. Lomefloxacin and sparfloxacin caused erythema and oedema which were often severe and lasted the full 7 days of the study. Enoxacin caused a long-lasting erythema, while the erythema seen following the administration of grepafloxacin, ciprofloxacin and **ofloxacin** was relatively mild and short-lived. The results of this study demonstrate the good safety profile of grepafloxacin in terms of phototoxicity.
CT Check Tags: Animal; Comparative Study; Female
Alopecia: CI, chemically induced
*Anti-Infective Agents, Fluoroquinolone: TO, toxicity
*Dermatitis, Phototoxic
Edema: CI, chemically induced
Erythema: CI, chemically induced
Mice
Mice, Inbred BALB C
*Piperazines: TO, toxicity
*Quinolones: TO, toxicity
*Skin: DE, drug effects
Skin: ME, metabolism
Skin: RE, radiation effects
Ultraviolet Rays
RN 119914-60-2 (grepafloxacin)
CN 0 (Anti-Infective Agents, Fluoroquinolone); 0 (Piperazines); 0 (Quinolones)

L136 ANSWER 6 OF 8 MEDLINE
AN 97134739 MEDLINE
DN 97134739 PubMed ID: 8980299
TI **Telomerase** activity concentrates in the mitotically active segments of human hair follicles.
AU Ramirez R D; Wright W E; Shay J W; Taylor R S
CS Department of Cell Biology, The University of Texas Southwestern Medical Center at Dallas, 75235-9069, USA.
NC T32-GM7062 (NIGMS)
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1997 Jan) 108 (1) 113-7.
Journal code: 0426720. ISSN: 0022-202X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English

FS Priority Journals
EM 199701
ED Entered STN: 19970219
Last Updated on STN: 19970219
Entered Medline: 19970121
AB **Telomerase** is a ribonucleoprotein enzyme capable of adding hexanucleotide repeats onto the ends of linear chromosomal DNA. Whereas normal somatic cells with a limited replicative capacity fail to express **telomerase** activity, most immortal eukaryotic cells do. Cells of renewal tissues (e.g., skin, intestine, blood) require an extensive proliferative capacity. Some cells in such renewal tissues also express **telomerase** activity, most likely to prevent rapid erosion of their telomeres during cell proliferation. In this study, we measured the levels of **telomerase** activity in dissected compartments of the human hair follicle: hair shaft, gland-containing fragment, upper intermediate fragment (where it is thought undifferentiated stem cells reside), lower intermediate fragment, and in the bulb-containing fragment (an area with high mitotic activity containing a more differentiated pool of keratinocytes). In anagen follicles, high levels of **telomerase** activity were found almost exclusively in the bulb-containing fragment of the follicles, with low levels of **telomerase** in the bulge area (intermediate fragments) and gland-containing fragment. In comparison, catagen follicles had low levels of **telomerase** activity in the bulb-containing fragments as well as in other compartments. Such observations indicate that, in anagen hair follicles, the fragments containing cells actively dividing (e.g., transient amplifying cells) express **telomerase** activity, whereas fragments containing cells with low mitotic activity, for example, quiescent stem cells, express low levels of **telomerase** activity.
CT Check Tags: Human; Male; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Adult
Aged
Aging: PH, physiology
Alopecia: EN, enzymology
***Hair Follicle: EN, enzymology**
Middle Age
Mitosis
Scalp: AH, anatomy & histology
***Telomerase: ME, metabolism**
CN EC 2.7.7.- (**Telomerase**)

L136 ANSWER 7 OF 8 MEDLINE
AN 96286322 MEDLINE
DN 96286322 PubMed ID: 8700796
TI **Alopecia** associated with **zidovudine** therapy.
AU Geletko S M; Segarra M; Mikolich D J
CS Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Providence, 02908, USA.
SO PHARMACOTHERAPY, (1996 Jan-Feb) 16 (1) 79-81.
Journal code: 8111305. ISSN: 0277-0008.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199609
ED Entered STN: 19960912
Last Updated on STN: 19970203
Entered Medline: 19960904
AB **Alopecia** has been described in patients infected with the human immunodeficiency virus (HIV). **Zidovudine** reportedly influences hair growth in these patients, causing regrowth or thickening. A 33-year-old HIV-infected man developed **alopecia** areata after

beginning **zidovudine** therapy. The **alopecia** reversed after the drug was discontinued.
CT Check Tags: Case Report; Human; Male
Adult
***Alopecia Areata: CI, chemically induced**
HIV Infections: DT, drug therapy
*Reverse Transcriptase Inhibitors: AE, adverse effects
Reverse Transcriptase Inhibitors: TU, therapeutic use
***Zidovudine: AE, adverse effects**
Zidovudine: TU, therapeutic use
RN **30516-87-1 (Zidovudine)**
CN 0 (Reverse Transcriptase Inhibitors)

L136 ANSWER 8 OF 8 MEDLINE
AN 73020252 MEDLINE
DN 73020252 PubMed ID: 4116662
TI Current status of new agents.
AU Carter S K
SO CANCER CHEMOTHERAPY REPORTS. PART 1, (1972 May) 3 (1) 33-47. Ref: 45
Journal code: 7607105. ISSN: 0069-0112.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 197212
ED Entered STN: 19900310
Last Updated on STN: 19970203
Entered Medline: 19721214
CT Check Tags: Animal; Human
Alopecia: CI, chemically induced
Antibiotics, Antineoplastic: TU, therapeutic use
Antineoplastic Agents: AE, adverse effects
*Antineoplastic Agents: TU, therapeutic use
Azacitidine: TU, therapeutic use
Azaguanine: TU, therapeutic use
Carmustine: TU, therapeutic use
Cyclohexanes: TU, therapeutic use
Drug Combinations: TU, therapeutic use
Heart: DE, drug effects
Leukemia L1210: DT, drug therapy
Nitrosourea Compounds: AD, administration & dosage
Nitrosourea Compounds: AE, adverse effects
Nitrosourea Compounds: TU, therapeutic use
Platinum: TU, therapeutic use
Prednisone: TU, therapeutic use
Remission, Spontaneous
RN 134-58-7 (Azaguanine); 154-93-8 (Carmustine); **320-67-2 (Azacitidine)**; 53-03-2 (Prednisone); 7440-06-4 (Platinum)
CN 0 (Antibiotics, Antineoplastic); 0 (Antineoplastic Agents); 0 (Cyclohexanes); 0 (Drug Combinations); 0 (Nitrosourea Compounds)

=> d all tot

L138 ANSWER 1 OF 4 MEDLINE
AN **94083248** MEDLINE
DN **94083248** PubMed ID: **8260344**
TI Increased nail and hair growth in a patient with AIDS.
AU Harindra V; Sivapalan S; Roy R B
CS Department of Genito-Urinary Medicine, Royal Victoria Hospital, Bournemouth.
SO BRITISH JOURNAL OF CLINICAL PRACTICE, (1993 Jul-Aug) 47 (4) 215-6.

Journal code: 0372546. ISSN: 0007-0947.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199401
ED Entered STN: 19940209
Last Updated on STN: 19970203
Entered Medline: 19940127
AB A variety of nail and hair changes have been described in AIDS patients, but rapid nail growth has not previously been reported. A slowing of nail growth would be expected in these patients due to immunosuppression and possible malnutrition. We report a case of increased nail and hair growth in a man with AIDS.
CT Check Tags: Case Report; Human; Male
Acquired Immunodeficiency Syndrome: DT, drug therapy
Acquired Immunodeficiency Syndrome: IM, immunology
*Acquired Immunodeficiency Syndrome: PP, physiopathology
Adult
***Hair: GD, growth & development**
*Nails: GD, growth & development
Zidovudine: TU, therapeutic use
RN **30516-87-1 (Zidovudine)**

L138 ANSWER 2 OF 4 MEDLINE
AN **92363650** MEDLINE
DN **92363650** PubMed ID: **1500232**
TI Disorders of the nails and hair associated with human immunodeficiency virus infection.
AU Prose N S; Abson K G; Scher R K
CS Department of Dermatology, Duke University School of Medicine, Durham, North Carolina.
SO INTERNATIONAL JOURNAL OF DERMATOLOGY, (1992 Jul) 31 (7) 453-7. Ref: 53
Journal code: 0243704. ISSN: 0011-9059.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals; AIDS
EM 199209
ED Entered STN: 19920925
Last Updated on STN: 19970203
Entered Medline: 19920917
CT Check Tags: Human
*HIV Infections: CO, complications
HIV Infections: DT, drug therapy
***Hair Diseases: MI, microbiology**
*Nail Diseases: MI, microbiology
Pigmentation Disorders: CI, chemically induced
Pigmentation Disorders: MI, microbiology
Zidovudine: AE, adverse effects
RN **30516-87-1 (Zidovudine)**

L138 ANSWER 3 OF 4 MEDLINE
AN **92118278** MEDLINE
DN **92118278** PubMed ID: **1768394**
TI **Zidovudine**-associated hypertrichosis and nail pigmentation in an HIV-infected patient.
AU Sahai J; Conway B; Cameron D; Garber G
SO AIDS, (1991 Nov) 5 (11) 1395-6.
Journal code: 8710219. ISSN: 0269-9370.
CY United States

DT Letter
LA English
FS Priority Journals; AIDS
EM 199202
ED Entered STN: 19920315
Last Updated on STN: 19970203
Entered Medline: 19920224
CT Check Tags: Case Report; Human; Male
Adult
HIV Infections: DT, drug therapy
***Hypertrichosis: ET, etiology**
*Nails: DE, drug effects
*Pigmentation Disorders: CI, chemically induced
***Zidovudine: AE, adverse effects**
RN **30516-87-1 (Zidovudine)**

L138 ANSWER 4 OF 4 MEDLINE
AN **91251879** MEDLINE
DN **91251879** PubMed ID: **2041557**
TI Excessive growth of eyelashes in a patient with AIDS being treated with **zidovudine.**
AU Klutman N E; Hinthorn D R
SO NEW ENGLAND JOURNAL OF MEDICINE, (1991 Jun 27) 324 (26) 1896.
Journal code: 0255562. ISSN: 0028-4793.
CY United States
DT Letter
LA English
FS Abridged Index Medicus Journals; Priority Journals; AIDS
EM 199107
ED Entered STN: 19910728
Last Updated on STN: 19970203
Entered Medline: 19910708
CT Check Tags: Case Report; Human; Male
*Acquired Immunodeficiency Syndrome: DT, drug therapy
Adult
***Eyelashes: GD, growth & development**
***Hypertrichosis: CI, chemically induced**
***Zidovudine: AE, adverse effects**
RN **30516-87-1 (Zidovudine)**

=> d his

(FILE 'HOME' ENTERED AT 14:16:18 ON 01 OCT 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 14:16:37 ON 01 OCT 2002
E TTAGGGTTAGGGTTAGGG/SQEN
L1 57 S E3
E ACGTTGAGGGGCATC/SQEN
E ATGAAAATCAGGGTTAGG/SQEN
E CAGUUAGGGUUAG/SQEN

FILE 'REGISTRY' ENTERED AT 14:19:03 ON 01 OCT 2002
L2 8 S CAGUUAGGGUUAG/SQEN
L3 65 S L1,L2
L4 10 S L3 AND (PEPTIDE OR COMPLEX)
L5 55 S L3 NOT L4
E OFLOXACIN/CN
L6 1 S E3
L7 32 S C18H20FN3O4/MF AND NC2NC2/ES AND 4/NR
L8 17 S L7 AND NC2OC2-NC5-C6/ES
L9 15 S L8 AND 6 CARBOXYLIC

```
L10          12 S L9 AND 9 FLUORO
L11           6 S L10 AND 3 METHYL 10
L12           4 S L11 AND 4 METHYL
L13           3 S L12 NOT 11C#
                E TMP/CN
                E TMPY/CN
                E TELOMERASE/CN
L14           1 S E3
                E AZT/CN
L15           1 S E4
L16          40 S C10H13N5O4/MF AND OC4/ES AND NCNC3/ES
L17          16 S L16 AND AZIDO AND THYM?
L18           6 S L17 NOT (LABELED OR (D OR T)/ELS OR 11C# OR 13C# OR 14C# OR C
                E RUBROMYCIN/CN
L19           1 S E3
                E PURPUROMYCIN/CN
L20           1 S E3
                E DIDEOXYINOSINE/CN
L21           1 S E3
                E LEVOFLOXACIN/CN
L22           1 S E3
L23         122 S C18H20FN3O4/MF
L24          17 S L23 AND NC2NC2/ES AND NC2OC2-NC5-C6/ES
L25           0 S L24 NOT L8
L26           3 S L22,L13
                E CARBOVIR/CN
L27           1 S E3
L28          21 S C11H13N5O2/MF AND C5/ES AND NCNC2-NCNC3/ES
L29           9 S L28 AND 2 AMINO 1 9 DIHYDRO
L30           7 S L29 AND 4 HYDROXYMETHYL
L31           4 S L30 NOT (T/ELS OR 14C OR 3 HYDROXYMETHYL)
                E URSODEOXYCHOLIC ACID/CN
L32           1 S E3
                E DIAZAPHILONIC ACID/CN
L33           1 S E3
                E ALTERPERYLENOL/CN
L34           1 S E3
                E 5-AZACYTIDINE/CN
L35           1 S E3
                E FOMIVIRSEN/CN
L36           1 S E3
                E DIAZAPHILONIC ACID/CN
                E 2-(3-(TRIFLUOROMETHYL)PHENYL)ISOTHIAZOLIN-3-ONE/CN
                E 3,4,9,10-PERYLENETETRACARBOXYLIC DIIMIDE/CN
L37           1 S E3
                E 10H-INDOLO(3,2-B)QUINOLINE/CN
                E 10H-INDOLO(3,2-B)-QUINOLINE/CN

     FILE 'HCAPLUS' ENTERED AT 14:43:51 ON 01 OCT 2002
                E TMPYP4
L38          31 S E3
L39          38 S 3 DEOXY 2 3 DIDEHYDROTHYMIDINE
L40           1 S 2 3 TRIFLUOROMETHYL PHENYL ISOTHIAZOLIN 3 ONE
L41          27 S TMPI
L42           7 S 10H INDOLO 3 2 B QUINOLINE
L43           0 S 2 O MERNA TELOMERASE
L44           0 S 2 O ME RNA TELOMERASE
L45          49 S 2 (S) RNA (S) TELOMERASE
L46           1 S 2 (S) O (S) ME (L) RNA (S) TELOMERASE
L47           5 S 2 (S) O (S) MERNA (S) TELOMERASE
L48           2 S 2 (S) O (S) METHYL (S) RNA (S) TELOMERASE
L49           0 S 2 (S) O (S) ALKYL (L) RNA (S) TELOMERASE
L50           0 S 2 (S) O (S) ALK (L) RNA (S) TELOMERASE
```

```
L51           6 S L46-L48
L52          46 S L45 NOT L51

     FILE 'REGISTRY' ENTERED AT 14:51:41 ON 01 OCT 2002
L53           1 S 92739-63-4
L54           1 S 38673-65-3
L55         148 S 38673-65-3/CRN
L56           1 S 3056-17-5

     FILE 'HCAPLUS' ENTERED AT 14:54:36 ON 01 OCT 2002
                SEL RN L40

     FILE 'REGISTRY' ENTERED AT 14:55:09 ON 01 OCT 2002
L57           9 S E1-E9
L58           2 S L57 AND F/ELS
L59           1 S L58 AND 220862-87-3
L60          78 S L6,L13,L53,L54,L15,L19,L20,L56,L21,L1,L22,L26,L27,L31,L59,L32

     FILE 'HCAPLUS' ENTERED AT 14:58:56 ON 01 OCT 2002
                SEL RN L42

     FILE 'REGISTRY' ENTERED AT 14:59:00 ON 01 OCT 2002
L61         155 S E10-E164
L62          70 S L61 AND 4/NR
L63           1 S L62 AND C15H10N2
L64          56 S L62 AND 10H
L65          23 S L64 NOT O/ELS
                E 4493/RID
                E 4493.57/RID
L66         609 S E3
L67         371 S L66 AND 1/NC
L68          21 S L60 NOT L1,L2
L69          22 S L68,L63

     FILE 'HCAPLUS' ENTERED AT 15:04:06 ON 01 OCT 2002
                E STYCZYNSKI P/AU
L70          19 S E3-E8
                E AHLUWALIA G/AU
L71          69 S E3,E4,E9-E11
L72          78 S L70,L71
L73        2759 S L14
L74        3490 S TELOMERASE
L75        3493 S L73,L74
L76          64 S L75 (L) INHIBIT?(S)(I OR II OR III OR IV)
L77           2 S L75 (L) INHIBIT?()(I OR II OR III OR IV)

     FILE 'REGISTRY' ENTERED AT 15:08:36 ON 01 OCT 2002
L78           1 S 354817-15-5

     FILE 'HCAPLUS' ENTERED AT 15:09:05 ON 01 OCT 2002
L79         101 S L75 (L) INHIBIT?(L) (I OR II OR III OR IV)
L80         101 S L76,L77,L79
L81         101 S L73,L74 AND L80
L82        3493 S L75,L81
L83          44 S L1 OR L2
L84          47 S L51,L83
L85       13404 S L69

     FILE 'REGISTRY' ENTERED AT 15:11:57 ON 01 OCT 2002
                SEL RN L69
L86         415 S E1-E22/CRN

     FILE 'HCAPLUS' ENTERED AT 15:12:20 ON 01 OCT 2002
```

```
L87          552 S L86
L88        17254 S L38-L52,L82-L85,L87
L89         7608 S OXFLOXACIN OR AZT OR RUBROMYCIN OR PURPUROMYCIN OR DIDEOXYINO
L90           29 S FOMIVIRSEN OR CATION?(L)PROPHYRIN?
L91         2408 S ZIDOVUDINE
L92        19972 S L88-L91
L93           12 S L92 AND L72
                 E HAIR/CT
                 E E3+ALL
L94        12678 S E6,E5
L95         8391 S E10-E14
                 E E17+ALL
L96        13115 S E2
                 E E9+ALL
                 E E15+ALL
L97         1847 S E4
                 E E7+ALL
                 E E17+ALL
L98         6514 S E6,E7
                 E E9+ALL
                 E E19+ALL
L99          712 S E2
L100          29 S L72 AND L94-L99
L101          29 S L72 AND HAIR
L102          29 S L100,L101
L103           0 S L102 AND L93
L104           0 S L102 AND ?TELOMERAS?
L105          46 S L92 AND L94-L99
L106          54 S L92 AND HAIR
L107          63 S L105,L106
L108          45 S L107 AND (1 OR 62 OR 63)/SC,SX
L109          18 S L107 NOT L108
                 SEL DN AN L108 14 15 26 36 38 44 45
L110           7 S L108 AND E1-E21

     FILE 'HCAPLUS' ENTERED AT 15:40:43 ON 01 OCT 2002
                 SEL HIT RN L110

     FILE 'REGISTRY' ENTERED AT 15:41:05 ON 01 OCT 2002
L111           4 S E22-E25
L112          20 S L69 NOT L111

     FILE 'HCAPLUS' ENTERED AT 15:42:49 ON 01 OCT 2002

     FILE 'MEDLINE' ENTERED AT 15:43:16 ON 01 OCT 2002
L113       14486 S L69
L114       12676 S OFLOXACIN OR TMPYP4 OR AZT OR ZODOVUDIN? OR RUBROMYCIN? OR PU
L115          19 S 3 DEOXY 2 3 DIDEHYDROTHYMIDIN? OR 2 3 TRIFLUOROMETHYL PHENYL
L116           3 S 10H INDOLO 3 2 B QUINOLIN?
L117         131 S L45-L51
L118        3143 S L75
L119          53 S L76,L77
L120          53 S L79
L121       21706 S L113-L120
                 E HAIR/CT
                 E E3+ALL
L122       14834 S E4+NT
                 E HAIR DISEASE/CT
                 E E4+ALL
L123       11930 S E4+NT
L124       22610 S L121 OR ZIDOVUDIN?
L125          28 S L124 AND L122,L123
                 E SCALP/CT
```

```
                E E3+ALL
L126        6044 S E4
L127         852 S L123,L124 AND L126
L128           1 S L125 AND L127
L129          28 S L125,L128
L130           8 S L129 AND ALOPEC?
L131           1 S L129 AND HAIR(L)LOSS
L132           0 S L129 AND HAIR(L)LOSE
L133           0 S L129 AND HAIR(L)LOSING
L134           0 S L129 AND HAIR(L)LOST
L135           0 S L129 AND BALD?
L136           8 S L130,L131

     FILE 'MEDLINE' ENTERED AT 15:52:59 ON 01 OCT 2002
L137          20 S L129 NOT L136
                SEL DN AN 11 14 17 20
L138           4 S L137 AND E1-E12

=> d his

     (FILE 'HOME' ENTERED AT 14:16:18 ON 01 OCT 2002)
                SET COST OFF

     FILE 'REGISTRY' ENTERED AT 14:16:37 ON 01 OCT 2002
                E TTAGGGTTAGGGTTAGGG/SQEN
L1             57 S E3
                E ACGTTGAGGGGCATC/SQEN
                E ATGAAAATCAGGGTTAGG/SQEN
                E CAGUUAGGGUUAG/SQEN

     FILE 'REGISTRY' ENTERED AT 14:19:03 ON 01 OCT 2002
L2              8 S CAGUUAGGGUUAG/SQEN
L3             65 S L1,L2
L4             10 S L3 AND (PEPTIDE OR COMPLEX)
L5             55 S L3 NOT L4
                E OFLOXACIN/CN
L6              1 S E3
L7             32 S C18H20FN3O4/MF AND NC2NC2/ES AND 4/NR
L8             17 S L7 AND NC2OC2-NC5-C6/ES
L9             15 S L8 AND 6 CARBOXYLIC
L10            12 S L9 AND 9 FLUORO
L11             6 S L10 AND 3 METHYL 10
L12             4 S L11 AND 4 METHYL
L13             3 S L12 NOT 11C#
                E TMP/CN
                E TMPY/CN
                E TELOMERASE/CN
L14             1 S E3
                E AZT/CN
L15             1 S E4
L16            40 S C10H13N5O4/MF AND OC4/ES AND NCNC3/ES
L17            16 S L16 AND AZIDO AND THYM?
L18             6 S L17 NOT (LABELED OR (D OR T)/ELS OR 11C# OR 13C# OR 14C# OR C
                E RUBROMYCIN/CN
L19             1 S E3
                E PURPUROMYCIN/CN
L20             1 S E3
                E DIDEOXYINOSINE/CN
L21             1 S E3
                E LEVOFLOXACIN/CN
L22             1 S E3
L23           122 S C18H20FN3O4/MF
L24            17 S L23 AND NC2NC2/ES AND NC2OC2-NC5-C6/ES
```

```
L25           0 S L24 NOT L8
L26           3 S L22,L13
                E CARBOVIR/CN
L27           1 S E3
L28          21 S C11H13N5O2/MF AND C5/ES AND NCNC2-NCNC3/ES
L29           9 S L28 AND 2 AMINO 1 9 DIHYDRO
L30           7 S L29 AND 4 HYDROXYMETHYL
L31           4 S L30 NOT (T/ELS OR 14C OR 3 HYDROXYMETHYL)
                E URSODEOXYCHOLIC ACID/CN
L32           1 S E3
                E DIAZAPHILONIC ACID/CN
L33           1 S E3
                E ALTERPERYLENOL/CN
L34           1 S E3
                E 5-AZACYTIDINE/CN
L35           1 S E3
                E FOMIVIRSEN/CN
L36           1 S E3
                E DIAZAPHILONIC ACID/CN
                E 2-(3-(TRIFLUOROMETHYL)PHENYL)ISOTHIAZOLIN-3-ONE/CN
                E 3,4,9,10-PERYLENETETRACARBOXYLIC DIIMIDE/CN
L37           1 S E3
                E 10H-INDOLO(3,2-B)QUINOLINE/CN
                E 10H-INDOLO(3,2-B)-QUINOLINE/CN

     FILE 'HCAPLUS' ENTERED AT 14:43:51 ON 01 OCT 2002
                E TMPYP4
L38          31 S E3
L39          38 S 3 DEOXY 2 3 DIDEHYDROTHYMIDINE
L40           1 S 2 3 TRIFLUOROMETHYL PHENYL ISOTHIAZOLIN 3 ONE
L41          27 S TMPI
L42           7 S 10H INDOLO 3 2 B QUINOLINE
L43           0 S 2 O MERNA TELOMERASE
L44           0 S 2 O ME RNA TELOMERASE
L45          49 S 2 (S) RNA (S) TELOMERASE
L46           1 S 2 (S) O (S) ME (L) RNA (S) TELOMERASE
L47           5 S 2 (S) O (S) MERNA (S) TELOMERASE
L48           2 S 2 (S) O (S) METHYL (S) RNA (S) TELOMERASE
L49           0 S 2 (S) O (S) ALKYL (L) RNA (S) TELOMERASE
L50           0 S 2 (S) O (S) ALK (L) RNA (S) TELOMERASE
L51           6 S L46-L48
L52          46 S L45 NOT L51

     FILE 'REGISTRY' ENTERED AT 14:51:41 ON 01 OCT 2002
L53           1 S 92739-63-4
L54           1 S 38673-65-3
L55         148 S 38673-65-3/CRN
L56           1 S 3056-17-5

     FILE 'HCAPLUS' ENTERED AT 14:54:36 ON 01 OCT 2002
                SEL RN L40

     FILE 'REGISTRY' ENTERED AT 14:55:09 ON 01 OCT 2002
L57           9 S E1-E9
L58           2 S L57 AND F/ELS
L59           1 S L58 AND 220862-87-3
L60          78 S L6,L13,L53,L54,L15,L19,L20,L56,L21,L1,L22,L26,L27,L31,L59,L32

     FILE 'HCAPLUS' ENTERED AT 14:58:56 ON 01 OCT 2002
                SEL RN L42

     FILE 'REGISTRY' ENTERED AT 14:59:00 ON 01 OCT 2002
L61         155 S E10-E164
```

```
L62          70 S L61 AND 4/NR
L63           1 S L62 AND C15H10N2
L64          56 S L62 AND 10H
L65          23 S L64 NOT O/ELS
                E 4493/RID
                E 4493.57/RID
L66         609 S E3
L67         371 S L66 AND 1/NC
L68          21 S L60 NOT L1,L2
L69          22 S L68,L63

     FILE 'HCAPLUS' ENTERED AT 15:04:06 ON 01 OCT 2002
                E STYCZYNSKI P/AU
L70          19 S E3-E8
                E AHLUWALIA G/AU
L71          69 S E3,E4,E9-E11
L72          78 S L70,L71
L73        2759 S L14
L74        3490 S TELOMERASE
L75        3493 S L73,L74
L76          64 S L75 (L) INHIBIT?(S)(I OR II OR III OR IV)
L77           2 S L75 (L) INHIBIT?()(I OR II OR III OR IV)

     FILE 'REGISTRY' ENTERED AT 15:08:36 ON 01 OCT 2002
L78           1 S 354817-15-5

     FILE 'HCAPLUS' ENTERED AT 15:09:05 ON 01 OCT 2002
L79         101 S L75 (L) INHIBIT?(L) (I OR II OR III OR IV)
L80         101 S L76,L77,L79
L81         101 S L73,L74 AND L80
L82        3493 S L75,L81
L83          44 S L1 OR L2
L84          47 S L51,L83
L85       13404 S L69

     FILE 'REGISTRY' ENTERED AT 15:11:57 ON 01 OCT 2002
                SEL RN L69
L86         415 S E1-E22/CRN

     FILE 'HCAPLUS' ENTERED AT 15:12:20 ON 01 OCT 2002
L87         552 S L86
L88       17254 S L38-L52,L82-L85,L87
L89        7608 S OXFLOXACIN OR AZT OR RUBROMYCIN OR PURPUROMYCIN OR DIDEOXYINO
L90          29 S FOMIVIRSEN OR CATION?(L)PROPHYRIN?
L91        2408 S ZIDOVUDINE
L92       19972 S L88-L91
L93          12 S L92 AND L72
                E HAIR/CT
                E E3+ALL
L94       12678 S E6,E5
L95        8391 S E10-E14
                E E17+ALL
L96       13115 S E2
                E E9+ALL
                E E15+ALL
L97        1847 S E4
                E E7+ALL
                E E17+ALL
L98        6514 S E6,E7
                E E9+ALL
                E E19+ALL
L99         712 S E2
L100         29 S L72 AND L94-L99
```

```
L101          29 S L72 AND HAIR
L102          29 S L100,L101
L103           0 S L102 AND L93
L104           0 S L102 AND ?TELOMERAS?
L105          46 S L92 AND L94-L99
L106          54 S L92 AND HAIR
L107          63 S L105,L106
L108          45 S L107 AND (1 OR 62 OR 63)/SC,SX
L109          18 S L107 NOT L108
                 SEL DN AN L108 14 15 26 36 38 44 45
L110           7 S L108 AND E1-E21

     FILE 'HCAPLUS' ENTERED AT 15:40:43 ON 01 OCT 2002
                 SEL HIT RN L110

     FILE 'REGISTRY' ENTERED AT 15:41:05 ON 01 OCT 2002
L111           4 S E22-E25
L112          20 S L69 NOT L111

     FILE 'HCAPLUS' ENTERED AT 15:42:49 ON 01 OCT 2002

     FILE 'MEDLINE' ENTERED AT 15:43:16 ON 01 OCT 2002
L113       14486 S L69
L114       12676 S OFLOXACIN OR TMPYP4 OR AZT OR ZODOVUDIN? OR RUBROMYCIN? OR PU
L115          19 S 3 DEOXY 2 3 DIDEHYDROTHYMIDIN? OR 2 3 TRIFLUOROMETHYL PHENYL
L116           3 S 10H INDOLO 3 2 B QUINOLIN?
L117         131 S L45-L51
L118        3143 S L75
L119          53 S L76,L77
L120          53 S L79
L121       21706 S L113-L120
                 E HAIR/CT
                 E E3+ALL
L122       14834 S E4+NT
                 E HAIR DISEASE/CT
                 E E4+ALL
L123       11930 S E4+NT
L124       22610 S L121 OR ZIDOVUDIN?
L125          28 S L124 AND L122,L123
                 E SCALP/CT
                 E E3+ALL
L126        6044 S E4
L127         852 S L123,L124 AND L126
L128           1 S L125 AND L127
L129          28 S L125,L128
L130           8 S L129 AND ALOPEC?
L131           1 S L129 AND HAIR(L)LOSS
L132           0 S L129 AND HAIR(L)LOSE
L133           0 S L129 AND HAIR(L)LOSING
L134           0 S L129 AND HAIR(L)LOST
L135           0 S L129 AND BALD?
L136           8 S L130,L131

     FILE 'MEDLINE' ENTERED AT 15:52:59 ON 01 OCT 2002
L137          20 S L129 NOT L136
                 SEL DN AN 11 14 17 20
L138           4 S L137 AND E1-E12

     FILE 'BIOSIS' ENTERED AT 15:56:10 ON 01 OCT 2002
                 E STYCZYNSKI P/AU
L139          19 S E3-E6
                 E AHLUZALIA G/AU
                 E AHLUWALIA G/AU
```

```
L140          96 S E3,E4,E8,E9
L141         106 S L139,L140
L142           0 S L141 AND (L14 OR TELOMER?)
L143          26 S L141 AND HAIR

     FILE 'HCAPLUS, BIOSIS' ENTERED AT 15:57:42 ON 01 OCT 2002
L144          52 DUP REM L102 L143 (3 DUPLICATES REMOVED)

     FILE 'BIOSIS' ENTERED AT 15:58:24 ON 01 OCT 2002
L145           9 S L60 AND L141
L146           0 S L145 AND L143
```

```
     FILE 'USPATFULL, CA' ENTERED AT 12:29:00 ON 05 FEB 2002
L1          4603 S 82419-36-1/RN OR OFLOXACIN OR OFLOXACINE OR FLOXIN OR OCUFLOX
L2         75213 S TOPICAL?
L3           372 S L1 AND L2
L4         85787 S (APPLY OR APPLYING OR APPLICATION OR ADMINISTER OR ADMINISTER
L5           306 S L1 AND L4
L6         13982 S HAIR (P) (REDUCE OR REDUCING OR REDUCTION OR PREVENT OR PREVE
L7            27 S L5 AND L6
L8            24 S L7 AND PY<2000
L9            24 DUP REM L8 (0 DUPLICATES REMOVED)
L10         4084 S HAIR (3A) (REDUCE OR REDUCING OR REDUCTION OR PREVENT OR PREV
L11            3 S L5 AND L10
L12           22 S L8 NOT L11
L13            3 S L7 NOT L8
L14          279 S L5 NOT L7
L15           30 S L14 AND HAIR
L16           15 S L15 AND PY<2000
L17           15 S L15 NOT L16
L18           43 S L1 (P) L4
L19           41 S L18 NOT L15
L20            0 S L19 AND (HAIR OR HIRSUTISM)
L21           26 S L19 AND PY<2000
L22          587 S TELOMERASE (3A) INHIBIT?
L23            2 S L6 AND L22
L24            6 S L1 AND L22
L25         1346 S 219522-15-3/RN OR 118120-51-7/RN OR 100986-85-4/RN OR LEVOFLO
```

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 144245-52-3 REGISTRY
CN DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Deoxyribonucleic acid, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G)
OTHER NAMES:
CN **Fomivirsen**
CN ISIS 2922
FS NUCLEIC ACID SEQUENCE
MF C204 H263 N63 O114 P20 S20
CI MAN
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CEN, CIN, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, MRCK*, PROMT, TOXCENTER, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
34 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
34 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 82419-36-1 REGISTRY
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (.+-.)-
OTHER NAMES:
CN (.+-.)-Ofloxacin
CN 9-Fluoro-2,3-dihydro-3-methyl-10-(N-methylpiperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
CN 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
CN DL 8280
CN Floxin
CN HOE 280
CN Ocuflox
CN Oflox
CN **Ofloxacin**
CN Ofloxacine
CN ORF 18489
CN PT 01
CN Tarivid
CN Visiren
FS 3D CONCORD
DR 85344-55-4, 83380-47-6, 86784-41-0, 303013-04-9
MF C18 H20 F N3 O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIUDB, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO



514/230.2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3229 REFERENCES IN FILE CA (1967 TO DATE)
28 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3237 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 82419-36-1 REGISTRY
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (.+-.)-
OTHER NAMES:
CN (.+-.)-Ofloxacin
CN 9-Fluoro-2,3-dihydro-3-methyl-10-(N-methylpiperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
CN 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
CN DL 8280
CN Floxin
CN HOE 280
CN Ocuflox
CN Oflox
CN **Ofloxacin**
CN Ofloxacine
CN ORF 18489
CN PT 01
CN Tarivid
CN Visiren
FS 3D CONCORD
DR 85344-55-4, 83380-47-6, 86784-41-0, 303013-04-9
MF C18 H20 F N3 O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
DRUGUPDATES, EMBASE, IFICDB, IFIUDB, IPA, MEDLINE, MRCK*, PHAR,
PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USAN,
USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3229 REFERENCES IN FILE CA (1967 TO DATE)
28 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3237 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s e5 or e10
1 "OFLOXACIN HYDROCHLORIDE"/CN
1 "OFLOXACIN SODIUM SALT"/CN
L2 2 "OFLOXACIN HYDROCHLORIDE"/CN OR "OFLOXACIN SODIUM SALT"/CN

=> d ide 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 219522-15-3 REGISTRY
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, sodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Ofloxacin sodium salt**
MF C18 H20 F N3 O4 . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT
CRN (82419-36-1)



● Na

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2002 ACS
RN 118120-51-7 REGISTRY
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrochloride, (.+-.)-
OTHER NAMES:
CN **Ofloxacin hydrochloride**
MF C18 H20 F N3 O4 . x Cl H
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, DRUGUPDATES, IPA, TOXCENTER, TOXLIT
CRN (82419-36-1)



● x HCl

5 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 100986-85-4 REGISTRY
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-
OTHER NAMES:
CN (-)-Ofloxacin
CN (S)-(-)-Ofloxacin
CN (S)-Ofloxacin
CN Cravit
CN DR 3355
CN HR 355
CN Levaquin
CN **Levofloxacin**
CN RWJ 25213-097
CN Tavanic
FS STEREOSEARCH
MF C18 H20 F N3 O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN,
CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT,
RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1152 REFERENCES IN FILE CA (1967 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1158 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 138199-71-0 REGISTRY
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrate (2:1), (3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrate (2:1), (S)-
OTHER NAMES:
CN **Levofloxacin hydrate**
FS STEREOSEARCH
MF C18 H20 F N3 O4 . 1/2 H2 O
SR CA
LC STN Files: BEILSTEIN*, BIOTECHNO, CA, CAPLUS, DRUGPAT, DRUGUPDATES, EMBASE, IPA, PHAR, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
CRN (100986-85-4)

Absolute stereochemistry. Rotation (-).



●1/2 H_2O

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)